var title_f20_44_21184="TSB guide exchange transfusion";
var content_f20_44_21184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Guidelines for exchange transfusion in infants 35 or more weeks gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dashed lines for the first 24 hours indicate uncertainty due to a wide range of clinical circumstances and a range of responses to phototherapy. Immediate exchange transfusion is recommended if infant shows signs of acute bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, high pitched cry) or if TSB is &ge;5 mg/dL (85 &micro;mol/L) above these lines. Risk factors include isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis. Measure serum albumin and calculate B/A ratio. Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin. If infant is well and 35-37 6/7 wk (median risk) can individualize TSB levels for exchange based on actual gestational age. Note that these suggested levels represent a consensus of most of the committee but are based on limited evidence, and the levels shown are approximations. During birth hospitalization, exchange transfusion is recommended if the TSB rises to these levels despite intensive phototherapy. For readmitted infants, if the TSB level is above the exchange level, repeat TSB measurement every 2 to 3 hours and consider exchange if the TSB remains above the levels indicated after intensive phototherapy for 6 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2004; 114:297. Copyright &copy; 2004 The American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21184=[""].join("\n");
var outline_f20_44_21184=null;
var title_f20_44_21185="Hanging arm cast";
var content_f20_44_21185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hanging arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a hanging arm cast. This type of cast is used for angulated or displaced midshaft humerus fractures. The weight of the cast and forces achived through adjustment of the length of the sling and site of attachment of the sling to the cast at the wrist can help achieve acceptable reduction and healing of the fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21185=[""].join("\n");
var outline_f20_44_21185=null;
var title_f20_44_21186="EP study tracings RF catheter ablation of the AV junction in AF";
var content_f20_44_21186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of the AV junction in atrial fibrillation (AF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the region of the atrio- ventricular (AV) junction (HBE1-2, HBE3-4), and the right ventricular apex (RVA3- 4) in a patient with atrial fibrillation (AF). Application of radiofrequency (RF) energy from the tip of the mapping catheter (HBE1-2) causes complete AV nodal block; pacing (P) is initiated from the right ventricular apex. A permanent VVIR pacemaker was implanted, and the patient has noted a marked improvement in symptoms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21186=[""].join("\n");
var outline_f20_44_21186=null;
var title_f20_44_21187="Patient information: Vaccines for travel (The Basics)";
var content_f20_44_21187=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15744\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/46/34533\">",
"         Areas in Africa where yellow fever is present",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/5/38993\">",
"          Areas in Central and South America where yellow fever is present",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/26/38305\">",
"         Patient information: Typhoid fever (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines for travel (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-for-travel-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1484037824\">",
"      <span class=\"h1\">",
"       What are vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaccines are treatments used to prevent certain serious or deadly infections. They work by teaching the body how to fight the germs that cause the infections. Vaccines usually come in shots, but some come in pills. Vaccines are also called &ldquo;vaccinations&rdquo; or &ldquo;immunizations.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037831\">",
"      <span class=\"h1\">",
"       Why should I get vaccinated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different infections are found in different countries. People can get infections when they travel to other parts of the world. Getting vaccinated can help keep you from getting sick when you travel.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037838\">",
"      <span class=\"h1\">",
"       What vaccines do I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The vaccines that you will need depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What countries you will travel to and what time of the year you will travel",
"       </li>",
"       <li>",
"        How long you will stay, where you will stay, and what you will do there",
"       </li>",
"       <li>",
"        Your medical conditions",
"       </li>",
"       <li>",
"        Which vaccines you have had in the past",
"       </li>",
"       <li>",
"        If you have allergies to substances in the vaccines",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Once your doctor or nurse has this information, he or she will recommend certain vaccines for you to get. These might include vaccines to prevent one or more of the following infections:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Yellow fever &ndash; Yellow fever is found in parts of Africa and Central and South America (",
"        <a class=\"graphic graphic_figure graphicRef55488 \" href=\"UTD.htm?33/46/34533\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef64157 \" href=\"UTD.htm?38/5/38993\">",
"         figure 2",
"        </a>",
"        ). People can get it after being bitten by an infected mosquito. The infection can cause liver problems and is sometimes fatal. Some countries need proof that visitors have gotten this vaccine before they can enter the country.",
"       </li>",
"       <li>",
"        Typhoid &ndash; Typhoid is found in Asia, Africa, and Latin America. People can get it from drinking unclean water. It can cause a fever, rash, and belly pain.",
"       </li>",
"       <li>",
"        Hepatitis A &ndash; Hepatitis A is found all over the world. People can get it from eating or drinking unclean food or water. Hepatitis A can cause severe liver problems.",
"       </li>",
"       <li>",
"        Japanese encephalitis &ndash; Japanese encephalitis is found in parts of Asia. People can get it after being bitten by an infected mosquito. It can cause long-terms problems with the nervous system, and is sometimes fatal.",
"       </li>",
"       <li>",
"        Rabies &ndash; Rabies is found all over the world. People can get it after being bitten or scratched by an infected animal. Rabies can cause behavior changes, paralysis, or death. (Paralysis is when people are unable to move their arms or legs.) Most travelers do not need to be vaccinated against rabies, but some do.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you did not get certain vaccines when you were younger, you might need other vaccines, too. These can include vaccines to protect against:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Polio &ndash; Polio can cause muscle weakness and pain, and lead to long-term paralysis.",
"       </li>",
"       <li>",
"        Tetanus and diphtheria &ndash; Vaccines for these 2 diseases are usually combined in one shot. Tetanus causes the muscles to work abnormally. Diphtheria can cause a thick covering in the back of the throat that can lead to breathing problems.",
"       </li>",
"       <li>",
"        Measles &ndash; Measles can cause a rash, fever, and cough. It can lead to long-term problems of the lungs, ears, or brain.",
"       </li>",
"       <li>",
"        Hepatitis B &ndash; Hepatitis B can cause long-term liver problems or liver cancer.",
"       </li>",
"       <li>",
"        Meningococcus &ndash; Meningococcus is a germ that can cause a serious body-wide infection of the blood or the tissues around the brain and spinal cord.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037845\">",
"      <span class=\"h1\">",
"       How many vaccine doses do I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each vaccine is different. Some vaccines work after just one dose. Others need two or more doses to prevent an infection.",
"     </p>",
"     <p>",
"      Some vaccines prevent an infection for the rest of your life. Others do not. A &ldquo;booster&rdquo; is a vaccine dose given after a certain number of years. It reminds the body how to prevent an infection. People who got vaccines when younger might need booster doses before they travel.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037852\">",
"      <span class=\"h1\">",
"       When should I get vaccinated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most vaccines take 4 to 6 weeks to work. It can also take a few months to get all the doses you need. So it&rsquo;s important to talk to your doctor about travel vaccines as soon as you know your travel plans.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037859\">",
"      <span class=\"h1\">",
"       What side effects can vaccines cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, vaccines cause no side effects. When they do cause side effects, they can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness, mild swelling, or soreness where the shot was given",
"       </li>",
"       <li>",
"        A mild fever",
"       </li>",
"       <li>",
"        A mild rash",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Vaccines also sometimes cause more serious side effects, such as severe allergic reactions. But serious side effects are rare.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse what side effects to expect each time you get a vaccine. If you have a reaction or a problem after a vaccine, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037866\">",
"      <span class=\"h1\">",
"       What if I have an egg allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an egg allergy, let your doctor or nurse know. Some vaccines can have egg in them because of how they are made. Your doctor or nurse will tell you which vaccines are safe to get.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1484037873\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=see_link\">",
"       Patient information: Typhoid fever (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/44/21187?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15744 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21187=[""].join("\n");
var outline_f20_44_21187=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037824\">",
"      What are vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037831\">",
"      Why should I get vaccinated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037838\">",
"      What vaccines do I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037845\">",
"      How many vaccine doses do I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037852\">",
"      When should I get vaccinated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037859\">",
"      What side effects can vaccines cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037866\">",
"      What if I have an egg allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1484037873\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/46/34533\">",
"      Areas in Africa where yellow fever is present",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/5/38993\">",
"       Areas in Central and South America where yellow fever is present",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=related_link\">",
"      Patient information: Typhoid fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21188="CV mortality HTN over 65 years";
var content_f20_44_21188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Joint effect of systolic and diastolic blood pressure on mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 344px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among participants in the NHANES II who were &ge;65 years of age, the figure shows a three dimensional surface representing the relative risk for cardiovascular mortality (vertical axis) with different combinations of the diastolic blood pressure (right diagonal arrow axis) and the systolic blood pressure (left diagonal arrow axis). For a fixed diastolic blood pressure, for example, the effect of different systolic blood pressures can be evaluated by following the risk surface along lines parallel to the systolic blood pressure axis. This effect is known as the conditional effect of systolic blood pressure. Similarly, for a fixed systolic blood pressure, the conditional effect of diastolic blood pressure can be evaluated by following the risk surface along lines parallel to the diastolic blood pressure axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Pastor-Barriuso R, et al. Ann Intern Med 2003; 139:731.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21188=[""].join("\n");
var outline_f20_44_21188=null;
var title_f20_44_21189="Zolpidem: Patient drug information";
var content_f20_44_21189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zolpidem: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     see \"Zolpidem: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=see_link\">",
"     see \"Zolpidem: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambien CR&reg;;",
"     </li>",
"     <li>",
"      Ambien&reg;;",
"     </li>",
"     <li>",
"      Edluar&trade;;",
"     </li>",
"     <li>",
"      Intermezzo&reg;;",
"     </li>",
"     <li>",
"      Zolpimist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13452765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sublinox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703151",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zolpidem or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696510",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When sleep drugs are used nightly for more than a few weeks, they may not work as well to help you sleep. This is known as tolerance. Only use sleep drugs for a short time. If your sleep problems last, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take naps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ambien&reg;: If you wake up in the early morning, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug only for short periods of time (7 to 10 days).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2995559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray into mouth over the tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2893560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         <b>",
"          Under the tongue (sublingual) tablet:",
"         </b>",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Intermezzo&reg;: Take only if needed and if you have 4 or more hours of bedtime left.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11157 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21189=[""].join("\n");
var outline_f20_44_21189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236158\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452765\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019083\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019085\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019084\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019089\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019090\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019092\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019087\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019088\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019093\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019094\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=related_link\">",
"      Zolpidem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=related_link\">",
"      Zolpidem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21190="TMEP II";
var content_f20_44_21190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Cutaneous mastocytosis - Telangiectasia macularis eruptiva perstans (TMEP) form",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Telangiectasia macularis eruptiva perstans type of maculopapular CM. Lesions are strictly macular (ie not elevated), reddish-brown and as shown in the higher magnification; (B) are ill-defined and exhibit fine telangiectasias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff, K, Komar, M, Petzelbaur, P. Clinical and histopathological aspects of cutaneous mastocytosis. Leukemia Research 2001; 25:519. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21190=[""].join("\n");
var outline_f20_44_21190=null;
var title_f20_44_21191="Tinzaparin: Drug information";
var content_f20_44_21191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tinzaparin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/61/16341?source=see_link\">",
"    see \"Tinzaparin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Innohep&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Low Molecular Weight Heparin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 mg of tinzaparin equals 70-120 units of anti-Xa activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A pharmacokinetic study confirmed that weight-based dosing (single doses of 75 or 175 units/kg) using actual body weight in heavy/obese patients between 100 and 165 kg led to achievement of similar anti-Xa activity levels compared to normal-weight patients (Hainer, 2002). However, there is limited clinical experience in patients with a BMI &gt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      DVT and/or PE treatment:",
"     </b>",
"     SubQ: 175 anti-Xa units/kg once daily (maximum: 18,000 anti-Xa units/day). The 2012",
"     <i>",
"      Chest",
"     </i>",
"     guidelines recommend starting warfarin on the first or second treatment day and continuing tinzaparin until INR is &ge;2 for at least 24 hours (usually 5-7 days) (Guyatt, 2012). Body weight dosing using prefilled syringes may also be considered. Refer to manufacturer labeling for detailed dosing recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      DVT prophylaxis:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hip replacement surgery:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians recommends initiation of LMWH &ge;12 hours preoperatively",
"     <b>",
"      or",
"     </b>",
"     &ge;12 hours postoperatively; extended duration up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preoperative regimen: 50 anti-Xa units/kg given 2 hours preoperatively followed by 50 anti-Xa units/kg once daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postoperative regimen: 75 anti-Xa units/kg once daily, with initial dose given postoperatively and continued for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Knee replacement surgery:",
"     </i>",
"     75 anti-Xa units/kg once daily, with initial dose given postoperatively and continued for 7-10 days.",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians recommends initiation of LMWH &ge;12 hours preoperatively",
"     <b>",
"      or",
"     </b>",
"     &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt, 2012). Body weight dosing using prefilled syringes may also be considered. Refer to manufacturer labeling for detailed dosing recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      General surgery:",
"     </i>",
"     3500 anti-Xa units once daily, with initial dose given 2 hours prior to surgery and then continued postoperatively for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anticoagulant in extracorporeal circuit during hemodialysis (recommendations apply to stable patients with chronic renal failure):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dialysis session &le;4 hours (no hemorrhage risk):",
"     </i>",
"     Initial bolus (via arterial side of circuit or I.V.): 4500 anti-Xa units at beginning of dialysis; typically achieves plasma concentrations of 0.5-1 anti-Xa units/mL; may give larger bolus for dialysis sessions &gt;4 hours. For subsequent dialysis sessions, may adjust dose as necessary in increments of 500 anti-Xa units based on previous outcome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dialysis session &le;4 hours (hemorrhage risk):",
"     </i>",
"     Initial bolus (I.V. only): 2250 anti-Xa units at beginning of dialysis (do not add to dialysis circuit). A smaller second I.V. dose may be administered during dialysis sessions &gt;4 hours. For subsequent dialysis sessions, adjust dose as necessary to achieve plasma concentrations of 0.2-0.4 anti-Xa units/mL.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14639839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 mg of tinzaparin equals 70-120 units of anti-Xa activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      VTE treatment (unlabeled use; Monagle, 2012):",
"     </b>",
"     SubQ: Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     May initiate a vitamin K antagonist on day 1 of tinzaparin therapy; discontinue tinzaparin on day 6 or later if INR is not &gt;2.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Birth to 2 months: 275 anti-Xa units/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-12 months: 250 anti-Xa units/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5 years: 240 anti-Xa units/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10 years: 200 anti-Xa units/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-16 years: 175 anti-Xa units/kg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Increased sensitivity to tinzaparin in elderly patients may be possible due to a decline in renal function. Use is not recommended in patients &gt;70 years of age with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, primarily undergoes renal elimination. Clearance is decreased in renal impairment; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Manufacturer&rsquo;s labeling suggests that a reduction in dose be considered but does not provide specific dose recommendations. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Does not undergo hepatic metabolism; however, has been associated with transient increases in transaminase levels; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14639452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Innohep&reg;: 10,000 anti-Xa units/mL (2 mL) [contains benzyl alcohol, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Innohep&reg;: 20,000 anti-Xa units/mL (0.5 mL, 0.7 mL, 0.9 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Innohep&reg;: 20,000 anti-Xa units/mL (2 mL) [contains benzyl alcohol, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Innohep&reg;: 10,000 anti-Xa units/mL (0.25 mL, 0.35 mL, 0.45 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient should be lying down or sitting. Administer by deep SubQ injection into the lower abdomen, outer thigh, lower back, or upper arm. Injection site should be varied daily. To minimize bruising, do not rub the injection site. In hemodialysis patients, may be administered I.V. (patients with high or low hemorrhage risk) or added to the dialyzer circuit (patients with low hemorrhage risk).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE) (except in patients with severe hemodynamic instability); prevention of venous thromboembolism (VTE) following orthopedic surgery or following general surgery in patients at high risk of VTE; prevention of clotting in indwelling intravenous lines and extracorporeal circuit during hemodialysis (in patients without high bleeding risk)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of tinzaparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.",
"     <b>",
"      Note:",
"     </b>",
"     Incidence not always reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2%), angina pectoris (&ge;1%), arrhythmia (&ge;1%), coronary thrombosis/MI (&ge;1%), dependent edema (&ge;1%), thromboembolism (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (2%), headache (2%), pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bullous eruption (&ge;1%), erythematous rash (&ge;1%), maculopapular rash (&ge;1%), skin necrosis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2%), abdominal pain (1%), constipation (1%), diarrhea (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding events (major events including intracranial, retroperitoneal, or bleeding into a major prosthetic joint: &le;3%; hemorrhage site not specified (2%); other bleeding events reported at an incidence of &ge;1% include anorectal bleeding, GI hemorrhage, hemarthrosis, hematemesis, hematuria, hemopericardium, injection site bleeding, melena, purpura, intra-abdominal bleeding, vaginal bleeding, wound hemorrhage), granulocytopenia (&ge;1%), thrombocytopenia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site cellulitis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (2%), dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (&ge;1%), neoplasm (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, angioedema, anaphylactoid reaction, GGT increased, hemoptysis, hypoaldosteronism, hyperkalemia, LDH increased, lipase increased, metabolic acidosis, ocular hemorrhage, osteopenia, osteoporosis, priapism, pruritus, rash, spinal epidural hematoma, Stevens-Johnson syndrome, thrombocytosis, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tinzaparin sodium, heparin or other low molecular weight heparins (LMWH), or any component of the formulation; active bleeding; history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia (HIT) or positive",
"     <i>",
"      in vitro",
"     </i>",
"     platelet-aggregation test in the presence of tinzaparin; acute or subacute endocarditis; generalized hemorrhage tendency and other conditions involving increased risks of hemorrhage (eg, severe hepatic insufficiency, imminent abortion); hemophilia or major blood clotting disorders; acute cerebral insult or hemorrhagic cerebrovascular accidents without systemic emboli; uncontrolled severe hypertension; diabetic or hemorrhagic retinopathy; injury or surgery involving the brain, spinal cord, eyes or ears; spinal/epidural anesthesia in patients requiring treatment dosages of tinzaparin; use of multidose vials containing benzyl alcohol in children &lt;2 years of age, premature infants, and neonates",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of tinzaparin in patients with current HIT or HIT with thrombosis is",
"     <b>",
"      not",
"     </b>",
"     recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP], 2012; Warkentin, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; history of hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmology surgery; those concomitantly treated with drugs that increase the risk of bleeding (eg, antiplatelet agents, anticoagulants); recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Withhold or discontinue for minor bleeding. Protamine infusion may be necessary for serious bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by suppressing aldosterone production; similar reactions could occur with LMWHs. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Cases of thrombocytopenia including thrombocytopenia with thrombosis have occurred. Use with caution in patients with history of thrombocytopenia (drug-induced or congenital) or platelet defects; monitor platelet count closely. Use is contraindicated in patients with history of confirmed or suspected heparin-induced thrombocytopenia (HIT) or positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of tinzaparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or thrombosis develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytosis: Asymptomatic thrombocytosis has been observed with use, particularly in patients undergoing orthopedic surgery or with concurrent inflammatory process; discontinue use with increased platelet counts and evaluate the risks/necessity of further therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI ulceration: Use with caution in patients with history of GI ulcer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in hepatic impairment; associated with transient, dose-dependent increases in AST/ALT which typically resolve within 2-4 weeks of therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prosthetic heart valves: Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with LMWHs. Pregnant women may be at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in renal impairment; clearance is decreased in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute; consider dosage reduction in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution due to increased bleeding risks. Use is not recommended in patients &gt;70 years of age with renal impairment. In a trial terminated early, an increase in all-cause mortality has been observed in patients &ge;70 years (mean age: &gt;82 years) with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute treated with tinzaparin compared to unfractionated heparin for acute DVT and/or PE (Leizorovicz, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extreme body weights: Use with caution in patients &lt;45 kg or &gt;120 kg; limited experience in these patients. Individualized clinical and laboratory monitoring are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Dosage forms that contain benzyl alcohol should not be used in pregnant women. In premature infants and neonates, large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with fatal toxicity (\"gasping syndrome\").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porcine intestinal mucosa: This product is derived from porcine intestinal mucosa and should not be used in patients allergic to pork products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Some dosage forms contain sodium metabisulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is observed more frequently in asthmatics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For subcutaneous use only; do not administer I.M. and avoid I.M. administration of other medications due to the risk of hematoma formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia: Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal) or spinal puncture in patients anticoagulated with LMWH or heparinoids. Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as traumatic or repeated epidural or spinal punctures. Avoid invasive spinal procedures for 12 hours following tinzaparin administration and withhold the next tinzaparin dose for at least 2 hours after the spinal procedure. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin (Low Molecular Weight) may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic doses of LMW heparins should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic LMW heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin (Low Molecular Weight).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal reproduction studies. Tinzaparin does not cross the human placenta. A pharmacokinetic study in pregnant women found no dose adjustment was needed during pregnancy. Vaginal bleeding was reported in ~10% of pregnant patients during tinzaparin therapy. LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors. LMWH should be discontinued prior to induction of labor or a planned cesarean delivery. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012). Contains benzyl alcohol; use with caution in pregnant women due to association with gasping syndrome in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14182386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of LMWH have been detected in breast milk; however, because it has a low oral bioavailability, it is unlikely to cause adverse events in a nursing infant. Use of LMWH may be continued in breast-feeding women (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (at baseline then twice weekly throughout therapy); renal function (use Cockcroft-Gault formula); hepatic function; potassium (baseline in patients at risk for hyperkalemia, monitor regularly if duration &gt;7 days); stool for occult blood. Routine monitoring of anti-Xa levels is generally not recommended; however, anti-Xa levels may be beneficial in certain patients (eg, children, obese patients, patients with severe renal insufficiency receiving therapeutic doses, and possibly pregnant women receiving therapeutic doses) (Guyatt, 2012). Peak anti-Xa levels are measured 4-6 hours after administration. Monitoring of PT and/or aPTT is not of clinical benefit.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F14182843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-Xa level  (measured 4 hours after administration): Fixed-dose (3500 units): 0.15 anti-Xa units/mL; weight-based (75-175 units/kg): 0.34-0.70 anti-Xa units/mL; in treatment of venous thromboembolism, a target of 0.85 anti-Xa units/mL has been recommended (Garcia, 2012)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children: Target anti-Xa level: 0.5-1 anti-Xa units/mL 4-6 hours after administration or 0.5-0.8 anti-Xa units/mL 2-6 hours after administration (Monagle, 2012)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Innohep (AR, BE, BG, CO, DE, DK, ES, FI, FR, GB, GR, HK, IE, IT, LU, MY, NL, NO, NZ, PH, PK, PT, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      innohep (CH);",
"     </li>",
"     <li>",
"      Logiparin (AT, CZ, IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tinzaparin is a low molecular weight heparin (average molecular weight ranges between 5500 and 7500 daltons, distributed as &lt;2000 daltons [&lt;10%], 2000-8000 daltons [60% to 72%], and &gt;8000 daltons [22% to 36%]) that binds antithrombin III, enhancing the inhibition of several clotting factors, particularly factor Xa. Tinzaparin anti-Xa activity (70-120 units/mg) is greater than anti-IIa activity (~55 units/mg) and it has a higher ratio of antifactor Xa to antifactor IIa activity compared to unfractionated heparin. Low molecular weight heparins have a small effect on the activated partial thromboplastin time.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Values reflective of anti-Xa activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Detectable anti-Xa activity persists for 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow; absorption half-life ~3 hours after subcutaneous administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 4 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Does not undergo hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 82 minutes;  prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MK, Garcia DA, Wren SM, et al, &ldquo;Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e227-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/22315263/pubmed\" id=\"22315263\" target=\"_blank\">",
"        22315263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hainer JW, Barrett JS, Assaid CA, et al, &ldquo;Dosing in Heavy-weight/Obese Patients With the LMWH, Tinzaparin: A Pharmacodynamic Study,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2002, 87(5):817-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/12038783/pubmed\" id=\"12038783\" target=\"_blank\">",
"        12038783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hull RD, Raskob GE, Pineo GF, et al, &ldquo;Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(15):975-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/1545850/pubmed\" id=\"1545850\" target=\"_blank\">",
"        1545850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leizorovicz A, Siguret V, Mottier D, &ldquo;Safety Profile of Tinzaparin versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis: The Innohep&reg; in Renal Insufficiency Study (IRIS),&rdquo;",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2011, 128(1):27-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/21477846/pubmed\" id=\"21477846\" target=\"_blank\">",
"        21477846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagge J, Jackevicius C, Dzavik V, et al, &ldquo;Acute Profound Thrombocytopenia Associated With Eptifibatide Therapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(3):374-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/12627937/pubmed\" id=\"12627937\" target=\"_blank\">",
"        12627937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonneau G, Sors H, Charbonnier B, et al, &ldquo;A Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin for Acute Pulmonary Embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(10):663-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/9278462/pubmed\" id=\"9278462\" target=\"_blank\">",
"        9278462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1286-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/44/21191/abstract-text/11320387/pubmed\" id=\"11320387\" target=\"_blank\">",
"        11320387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10009 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-CE64EF4B76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21191=[""].join("\n");
var outline_f20_44_21191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228098\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228132\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228100\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14639839\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228101\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228102\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228103\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14639452\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228078\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228076\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228130\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228081\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228063\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300143\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228068\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228084\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228107\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182386\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228073\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182843\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228085\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228062\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228080\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/61/16341?source=related_link\">",
"      Tinzaparin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21192="Prognostic factors in patients with renal cell carcinoma";
var content_f20_44_21192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognostic factors in patients with renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21192/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/44/21192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms' tumor) is common in children (5 to 6 percent of primary renal tumors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When patients with RCC present with localized disease, surgical resection can be curative. Unfortunately, many RCCs are clinically silent for much of their natural history. Thus, the diagnosis is frequently not made until disease is either locally advanced and unresectable or metastatic. Furthermore, many patients who initially are resectable eventually recur. The prognosis for long-term disease-free survival for patients with locally advanced or metastatic RCC is generally poor.",
"   </p>",
"   <p>",
"    The factors affecting prognosis in patients with RCC will be reviewed here. An overview of the approach to treatment is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link\">",
"     \"Overview of the treatment of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMIC EXTENT OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastasis (TNM) staging system is used to assess the anatomic extent of disease (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/1\">",
"     1",
"    </a>",
"    ]. The anatomic extent of disease is the most consistent factor that influences prognosis in patients with RCC (",
"    <a class=\"graphic graphic_figure graphicRef59133 \" href=\"UTD.htm?3/38/3695\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'TNM staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314655\">",
"    <span class=\"h2\">",
"     Stage I/II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage I (T1N0) RCC have a five-year survival rate over 90 percent in most contemporary series. The survival rate may be slightly lower for patients with stage II (T2N0) disease, with reported five-year survival rates ranging from 75 to 95 percent.",
"   </p>",
"   <p>",
"    Patients with stage I or II RCC that invades the urinary collecting system appear to have a significantly worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/2\">",
"     2",
"    </a>",
"    ]. In a multivariate analysis of a series of 1124 cases of RCC, the 10-year survival rates for patients with T1 or T2 primary lesions that invaded the urinary collecting system was 43 and 41 percent, respectively (hazard ratio 3.2, 95% CI 1.4-7.1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314662\">",
"    <span class=\"h2\">",
"     Stage III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported five-year survival rate for patients with stage III RCC (T1N1M0, T2N1M0, T3N0M0, or T3N1M0) who undergo nephrectomy ranges from 59 to 70 percent. There are conflicting data about whether extension into the perinephric fat (T3a) alone adversely affects prognosis. Two large studies could not demonstrate a difference when T3a primary tumors were compared to comparably sized T1 and T2 primary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast, involvement of perinephric fat remained a prognostic factor in a third series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients with T3a disease, the size of the primary tumor remains a prognostic factor (ten-year survival rates of 77, 54, and 46 percent for tumors &lt;4, 4 to 7, and &gt;7 cm, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with involvement of the renal vein or inferior vena cava are classified as stage III. Although some studies have not identified an adverse impact of renal vein involvement on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], other reports found that the extent of vena cava invasion and the anatomic location of the tumor thrombus were important prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The extent of venous involvement is recognized in the AJCC system, with T3a tumors having tumor invasion of the renal vein or its branches, T3b having gross involvement of the IVC below the diaphragm, and T3c lesions have tumor invading the wall of the inferior vena cava (IVC) or grossly extending into the IVC above the diaphragm.",
"   </p>",
"   <p>",
"    In addition, invasion of the urine collecting system also appears to be a prognostic factor in patients with stage III RCC. In a series of 303 cases with stage III disease, multivariate analysis found that patients with urine collecting system invasion had significantly worse disease-specific and overall survival compared with those without invasion (five-year rates 34 versus 59 percent and 30 versus 52 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314683\">",
"    <span class=\"h2\">",
"     Stage IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival for patients with stage IV disease (T4 primary tumor, N2 involvement, or distant metastases) is 16 to 20 months in contemporary reports, and the five-year survival rate is less than 10 percent for patients with distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, some contemporary studies using newer antiangiogenic and targeted therapies have reported median survival in excess of two years from study entry in patients who meet protocol eligibility criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314835\">",
"    <span class=\"h2\">",
"     Tumor type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the tumor subtype (ie, clear cell versus papillary or chromophobe carcinoma) affects prognosis is controversial. A multi-institution study failed to identify a prognostic difference in over 4000 patients when TNM stage, histologic grade, and performance status were considered in a multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, multivariate analyses of single institution series from the Mayo Clinic and from Memorial Sloan-Kettering Cancer Institute, including 3062 and 1668 patients, respectively, both found that patients with clear cell histology had significantly poorer cancer-specific survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some less common variants, including collecting duct carcinomas, sarcomatoid clear cell carcinomas, and renal medullary carcinomas, are considered more aggressive and are associated with a shorter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314828\">",
"    <span class=\"h2\">",
"     Tumor grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic grade is an independent factor correlating with survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. Multiple systems are used to grade RCC, of which the Fuhrman's grade is the most widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In one report, the five-year survival rate based upon tumor grade was 89, 65, and 46 percent for tumors of histologic grade 1, 2, and 3 to 4, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the anatomic extent of disease, clinical factors can influence survival. Negative prognostic signs include a poor performance status, the presence of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paraneoplastic syndromes (eg, anemia, hypercalcemia, hepatopathy, thrombocytosis, fever, weight loss), and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11,19,24-28\">",
"     11,19,24-28",
"    </a>",
"    ]. Although younger patients (ie, 20 to 40 years old) are more likely to be symptomatic at presentation, their outcome may be slightly better due to a lower incidence of nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple models have been developed to integrate the information from anatomic staging with histopathology and clinical prognostic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. The most widely studied prognostic model has been the UCLA integrated staging system (UISS) (",
"    <a class=\"graphic graphic_table graphicRef77502 \" href=\"UTD.htm?27/1/27676\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/30\">",
"     30",
"    </a>",
"    ]. The UISS incorporates the Eastern Cooperative Oncology Group performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    ) and Fuhrman's histologic grade (1 through 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/22\">",
"     22",
"    </a>",
"    ]) into the TNM anatomic staging system. Using these variables, five distinct prognostic categories were identified that correlate with post-nephrectomy outcome (",
"    <a class=\"graphic graphic_figure graphicRef66352 \" href=\"UTD.htm?17/50/18222\">",
"     figure 2",
"    </a>",
"    ). The value of this system has subsequently been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/19,35\">",
"     19,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MOLECULAR MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tissue microarrays permits the evaluation of the histologic and immunohistochemical features of multiple tumors simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This technology can achieve rapid molecular profiling and may identify definitive prognostic indicators for RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although none of these factors has an established role independent of stage, some markers have shown promise as prognostic markers in patients with clear cell RCC. In particular, lack of B7H1 and B7H4 expression in patients has been strong predictors of overall survival in patients without metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/38,41-43\">",
"     38,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical detection of carbonic anhydrase IX (CAIX) and the proliferative marker Ki67 has also been shown to correlate with prognosis. In a series of 224 patients with clear cell RCC, multivariate analysis found that low levels of CAIX expression and high levels of Ki67 were associated with a significantly worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/44\">",
"     44",
"    </a>",
"    ]. A combination of these two parameters was useful in separating patients into good, intermediate, and poor prognosis subsets. The role of carbonic anhydrase IX (CAIX) expression by the primary tumor as a predictor of responsiveness to immunotherapy remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Histology and CAIX expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, high levels of immunohistochemical expression of hypoxia-inducible factor (HIF)-1 alpha were associated with a significantly worse survival compared to tumors with lower levels of HIF-1 alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/45\">",
"     45",
"    </a>",
"    ]. However, at least one other study has suggested that patients with tumors that express HIF-1 alpha have a better prognosis than those with tumors that only express HIF-2 alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/46\">",
"     46",
"    </a>",
"    ]. The basis for this discrepancy and the overall significance of these findings for disease biology and treatment selection remains to be sorted out.",
"   </p>",
"   <p>",
"    Another potentially important marker is IMP3, one of the insulin-like growth factor mRNA binding proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In a study that correlated survival with immunohistochemical expression of IMP3 in 371 patients with localized primary tumors, expression of IMP3 was associated with significantly worse metastasis-free and overall survival (HRs 5.84, 95% CI 3.60-9.49 and 4.01, 95% CI 2.66-6.05, respectively). The prognostic importance of IMP3 appears to extend to papillary and chromophobe tumors, as well as clear cell RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific molecular markers are already being integrated into staging systems. For example, the UCLA group has identified a pattern of immunohistochemical markers expression (PTEN, CAIX, pAKT, etc.) that appears to largely replace clinical and staging criteria as prognostic markers.",
"   </p>",
"   <p>",
"    Another cytogenetic marker that may convey clinically important prognostic information is deletion of chromosome 9p in patients with clear cell RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. In the largest study, chromosome 9p was deleted in 97 of 703 patients (14 percent) with clear cell RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients with this deletion had more aggressive disease at presentation, manifested by significantly larger tumors, higher Fuhrman grade, and an increased frequency of lymph node and distant metastasis. In addition, on multivariate analysis, deletion of chromosome 9p was associated with an increased risk of disease recurrence in patients with small (&lt;4 cm) solitary renal masses (hazard ratio 6.65, 95% CI 1.33-33.3). The gene associated with this increased risk has not been identified.",
"   </p>",
"   <p>",
"    Gene expression profiling offers another approach to further define prognosis based on the expression pattern of various genes. This work is primarily experimental and in the past has been limited by the requirement that tissue specimens be collected and frozen under strict conditions for mRNA analysis. Newer techniques, such as the cDNA-mediated annealing, selection, extension, and ligation (DASL) assay, may eventually circumvent some of these difficulties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS IN STAGE IV DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prognosis for patients with recurrent or metastatic RCC is poor (",
"    <a class=\"graphic graphic_figure graphicRef59133 \" href=\"UTD.htm?3/38/3695\">",
"     figure 1",
"    </a>",
"    ), many studies have documented longer survival in patients with specific clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11,54-58\">",
"     11,54-58",
"    </a>",
"    ]. These include a long interval between nephrectomy and the appearance of distant metastases, a single site of metastatic disease, and the absence of retroperitoneal adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11,12,59\">",
"     11,12,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five additional factors that predicted shortened survival were identified by multivariate analysis in a series of 670 patients with advanced RCC treated at Memorial Sloan-Kettering Cancer Center (MSKCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Karnofsky performance status (KPS) of &lt;80 percent (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum lactic dehydrogenase (LDH) level &gt;1.5 times the upper limit of normal",
"     </li>",
"     <li>",
"      Corrected serum calcium &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Hemoglobin concentration less than the lower limit of normal",
"     </li>",
"     <li>",
"      Absence of nephrectomy (ie, no disease-free interval)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with none of these risk factors versus those with one or two versus those with three or more risk factors had significantly higher survival rates at one year (71 versus 42 and 12 percent, respectively) and three years (31 versus 7 and 0 percent, respectively).",
"   </p>",
"   <p>",
"    A follow-up analysis that was limited to 463 patients who were initially treated with interferon-alfa (IFNa) identified an interval of less than one year from initial diagnosis to the start of IFNa therapy as an additional indicator of a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/60\">",
"     60",
"    </a>",
"    ]. In this report, the median survival duration for patients with zero, one or two, or three or more risk factors was 30, 14, and 5 months, respectively.",
"   </p>",
"   <p>",
"    The MSKCC prognostic model was validated and extended in a series of 353 previously untreated patients with metastatic RCC from the Cleveland Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition to the parameters already identified, there were two other significant negative prognostic factors: prior radiotherapy and the presence of more than one site of metastatic disease. Patients with favorable (no more than one poor prognostic factor), intermediate (two prognostic factors), or poor risk (more than two) disease had median survival durations of 26, 14, and 7 months, respectively.",
"   </p>",
"   <p>",
"    Contemporary trials in patients treated with agents targeting the vascular endothelial growth factor (VEGF) pathway have also been analyzed to define prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. As an example, prognosis was compared with baseline characteristics in 645 patients who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/63\">",
"     63",
"    </a>",
"    ]. On multivariate analysis, factors associated with poorer survival included KPS &lt;80, time from original diagnosis to treatment less than one year, hemoglobin less than the lower limit of normal, and serum calcium, neutrophil count, or platelet count greater than the upper limit of normal. The presence of bone metastases may also be an independent factor associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/64\">",
"     64",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Patients were divided into favorable risk (no adverse prognostic factors), intermediate risk (one or two adverse prognostic factors) or poor risk (three or more adverse prognostic factors) categories. The median survival for good-risk patients had not been reached and was 27 and 9 months, respectively, for the intermediate and poor-risk groups. The two-year survival rates for the three groups were 75, 53, and 7 percent, respectively.",
"   </p>",
"   <p>",
"    In addition to the prognostic implications, these factors are useful for determining which patients are candidates for specific therapeutic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H10#H10\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Predictors of response'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recurrence after nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same five MSKCC clinical factors that influence survival in patients with stage IV disease were analyzed in a series of 118 patients who all had developed a recurrence following nephrectomy for localized disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/65\">",
"     65",
"    </a>",
"    ]. The overall median survival was 21 months following recurrence. Patients with none of these risk factors constituted a low-risk group, while those with one or two risk factors had an intermediate risk and those with three or more were at high risk for shortened survival. Median survival for low-, intermediate-, and high-risk groups was 76, 25, and 6 months, respectively. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prognosis after failed immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with a shortened survival after failure on immunotherapy with interleukin-2 or interferon include the presence of more than one metastatic site, an interval of less than two years from nephrectomy to the development of metastatic disease, high serum alkaline phosphatase or LDH, and an abnormal corrected serum calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/66\">",
"     66",
"    </a>",
"    ]. In an analysis of a trial assessing shark cartilage in 300 patients who had failed prior immunotherapy, those treated with either the alternative medicine or with placebo, median survival ranged from 16 months in patients with none of these negative parameters to 3.5 months in patients with three or more factors.",
"   </p>",
"   <p>",
"    Although immunotherapy is now used much less frequently, this study provides baseline data for patients on clinical trial protocols in which newer treatments (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ) can be compared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that immunologic factors may influence the response to treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prognosis in patients with metastatic clear cell RCC. This was suggested by a study of 85 cases treated with IL-2, in which blood and tumor tissue was evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/67\">",
"     67",
"    </a>",
"    ]. Multivariate analysis confirmed the prognostic significance of clinical parameters identified by other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, a low CD57+ cell count in the biopsy sample, an increased blood neutrophil count, and the presence of neutrophils in the biopsy specimen were independently associated with a lower five-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, an abundance of arginase-producing CD11b+, CD14-, CD15+ myeloid-appearing cells were identified in the peripheral blood of patients with advanced RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/68\">",
"     68",
"    </a>",
"    ]. These cells correlated with the degree of immune dysfunction as measured by decreases in CD3 cell TCR zeta chain expression. The relationship of these PMN-like cells to the neutrophils described above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/67\">",
"     67",
"    </a>",
"    ] and to overall prognosis requires further investigation.",
"   </p>",
"   <p>",
"    Other evidence supporting a role for immunologic factors comes from an analysis of tumor expression of B7 regulatory molecules, which are known inhibitors of T-cell mediated immunity. Patients with RCC that express B7H1 and B7H4 on their cell surface are at significantly increased risk of death from RCC, an effect that persists after adjusting for age, tumor grade, and performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21192/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients presenting with renal cell carcinoma (RCC), the tumor node metastasis staging system provides the primary prognostic information (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59133 \" href=\"UTD.htm?3/38/3695\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomic extent of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional prognostic information can be provided from incorporating parameters such as the performance status and Fuhrman&rsquo;s histologic grade. These have been integrated with the anatomic stage in the UCLA integrated staging system (",
"      <a class=\"graphic graphic_table graphicRef77502 \" href=\"UTD.htm?27/1/27676\">",
"       table 2",
"      </a>",
"      ). Ongoing research studies indicate that molecular markers may also be useful. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Molecular markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic (stage IV) disease, multiple clinical parameters have been identified that are associated with prognosis. These include a poor performance status, an elevated serum lactic dehydrogenase (LDH), and elevated serum calcium, anemia, and the presence of metastatic disease at the initial presentation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognostic factors in stage IV disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kidney. In: AJCC Cancer Staging Manual, Springer, New York 2009. p.479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/2\">",
"      Verhoest G, Avakian R, Bensalah K, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009; 182:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/3\">",
"      Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 2005; 173:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/4\">",
"      Gilbert SM, Murphy AM, Katz AE, et al. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 2006; 68:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/5\">",
"      Siddiqui SA, Frank I, Leibovich BC, et al. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol 2007; 177:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/6\">",
"      Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979; 122:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/7\">",
"      Ficarra V, Righetti R, D'Amico A, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001; 61:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/8\">",
"      Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/9\">",
"      Cherrie RJ, Goldman DG, Lindner A, deKernion JB. Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982; 128:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/10\">",
"      Anderson CB, Clark PE, Morgan TM, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology 2011; 78:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/11\">",
"      Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/12\">",
"      Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/13\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/14\">",
"      Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/15\">",
"      Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010; 183:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/16\">",
"      Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol 2009; 182:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/17\">",
"      Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/18\">",
"      Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/19\">",
"      Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/20\">",
"      Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988; 61:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/21\">",
"      Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007; 177:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/22\">",
"      Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/23\">",
"      Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 2007; 109:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/24\">",
"      Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/25\">",
"      Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/26\">",
"      Fahn HJ, Lee YH, Chen MT, et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 1991; 145:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/27\">",
"      Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol 2004; 172:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/28\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/29\">",
"      Siemer S, Hack M, Lehmann J, et al. Outcome of renal tumors in young adults. J Urol 2006; 175:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/30\">",
"      Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/31\">",
"      Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001; 58:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/32\">",
"      Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/33\">",
"      Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/34\">",
"      Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/35\">",
"      Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001; 19:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/36\">",
"      Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001; 98:9754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/37\">",
"      Junker K, Moravek P, Podhola M, et al. Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: correlation with clinical and histological data. Int J Oncol 2000; 17:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/38\">",
"      Kosari F, Parker AS, Kube DM, et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005; 11:5128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/39\">",
"      Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11:5730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/40\">",
"      Gonzalgo ML, Yegnasubramanian S, Yan G, et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 2004; 10:7276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/41\">",
"      Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/42\">",
"      Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 2005; 173:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/43\">",
"      Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006; 5:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/44\">",
"      Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004; 171:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/45\">",
"      Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:7388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/46\">",
"      Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/47\">",
"      Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/48\">",
"      Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008; 112:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/49\">",
"      Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008; 112:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/50\">",
"      La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010; 116:4696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/51\">",
"      Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/52\">",
"      Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/53\">",
"      Presti JC Jr, Wilhelm M, Reuter V, et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002; 167:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/54\">",
"      Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/55\">",
"      Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/56\">",
"      Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/57\">",
"      Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/58\">",
"      Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/59\">",
"      Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/60\">",
"      Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004; 10:6302S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/61\">",
"      Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/62\">",
"      Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/63\">",
"      Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/64\">",
"      Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/65\">",
"      Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/66\">",
"      Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/67\">",
"      Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/68\">",
"      Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/69\">",
"      Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21192/abstract/70\">",
"      Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006; 103:10391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2961 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21192=[""].join("\n");
var outline_f20_44_21192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMIC EXTENT OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314655\">",
"      Stage I/II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314662\">",
"      Stage III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314683\">",
"      Stage IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314835\">",
"      Tumor type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314828\">",
"      Tumor grade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MOLECULAR MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSTIC FACTORS IN STAGE IV DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recurrence after nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prognosis after failed immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2961|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/38/3695\" title=\"figure 1\">",
"      Stage-based survival in patients with RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/50/18222\" title=\"figure 2\">",
"      Prognosis RCC by UISS stage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15213\" title=\"table 1\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/1/27676\" title=\"table 2\">",
"      Renal cell CA UISS categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 3\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=related_link\">",
"      Overview of the treatment of renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21193="Vitiligo";
var content_f20_44_21193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vitiligo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21193/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/44/21193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitiligo is an acquired skin depigmentation occurring in approximately 1 percent of the population worldwide. It results from an autoimmune process directed against the melanocytes. The disease can be devastating psychologically, particularly in dark-skinned individuals. In the United States, the National Vitiligo Foundation provides additional support and information for patients (",
"    <a class=\"external\" href=\"file://nvfi.org/\">",
"     nvfi.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise cause of vitiligo is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/1\">",
"     1",
"    </a>",
"    ]. Genetic factors appear to play a role; 20 to 30 percent of patients may have a family history of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis is thought to involve an autoimmune process directed against melanocytes. Evidence of this is derived from histologic studies that have found an absence of melanocytes in the affected skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/4\">",
"     4",
"    </a>",
"    ]. An autoimmune process is also suggested by the concomitant occurrence of other autoimmune diseases in patients with vitiligo. Alterations in both cellular and humoral immunity have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supports cellular immunity as an important factor in the development of vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/5\">",
"     5",
"    </a>",
"    ]. CD8+ T cell predominant infiltrates have been found in perilesional skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], and CD8+ cytotoxic T cells have been identified adjacent to disappearing melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating melanocyte specific, CD8+ cytotoxic T lymphocytes have been detected in the peripheral blood of patients with vitiligo, but it is unconfirmed whether these T cells correlate with those found in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/5\">",
"     5",
"    </a>",
"    ]. The presence of the cutaneous lymphocyte antigen, a molecule involved in skin-homing, on many infiltrating T cells supports the hypothesis of recruitment of these cells from the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Humoral immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple autoantibodies against melanocyte antigens including tyrosinase, tyrosinase related proteins 1 and 2, Pmel17, SOX transcription factors, and melanin-concentrating hormone receptor 1 (MCHR1) have been detected in the sera of some patients with vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Whether these autoantibodies play a significant role in the pathogenesis of the disorder remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines may play an important role in the pathogenesis of vitiligo. Examples of abnormal cytokine profiles found in vitiligo include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interleukin (IL)-6 (an inhibitor of melanocyte proliferation), interferon (IFN)-gamma (an initiator of apoptosis), and tumor necrosis factor (TNF)-alpha (an inhibitor of melanocyte proliferation and initiator of apoptosis) levels were increased in vitiliginous skin compared with the skin of normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/8-11\">",
"       8-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of granulocyte-monocyte colony stimulating factor (GM-CSF), stem cell factor (SCF), and basic fibroblastic growth factor (bFGF), which serve a stimulatory function for pigment cells, was lower in vitiliginous skin than in perilesional skin, non-lesional skin, and the skin of normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased serum transforming growth factor (TGF)-beta levels have been found in patients with vitiligo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/12\">",
"       12",
"      </a>",
"      ]. The authors of this study hypothesized that low TGF-beta levels may increase the CD8+ lymphocyte response and decrease regulatory T cell maturation, causing impaired inhibition of inflammation in vitiligo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research is necessary to clarify cytokine profiles in vitiligo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Association with autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased frequencies of other autoimmune disorders, such as autoimmune thyroid disease, pernicious anemia, systemic lupus erythematosus, and Addison disease have been detected in patients with vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The association of vitiligo with these disorders suggests the presence of shared genetic factors that contribute to the development of these diseases. In genome wide association studies, several genes with known associations with other autoimmune disorders were identified as potential susceptibility loci for generalized vitiligo, including PTPN22, LPP, IL2RA, UBASH3A, C1QTNF6, and genes encoding MHC I and MHC II molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, vitiligo is a component of the polyglandular autoimmune syndrome type II, which is characterized by the presence of autoimmune thyroid disease (usually chronic autoimmune thyroiditis or Graves' disease), type 1 diabetes mellitus, primary adrenal insufficiency, and hypopituitarism, among other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A study performing genetic association analyses identified NALP1 as a candidate gene involved in this vitiligo-associated autoimmune syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/21\">",
"     21",
"    </a>",
"    ]; NALP1 encodes NACHT leucine-rich-repeat protein 1, which is a regulator of the innate immune system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with vitiligo have neither a family history of vitiligo nor a history of other autoimmune diseases. A number of other hypotheses have been proposed to explain the pathogenesis of this disorder, including an intrinsic abnormality of melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/22\">",
"     22",
"    </a>",
"    ], increased local catecholamine release [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/23\">",
"     23",
"    </a>",
"    ], inadequate defense from the toxic effects of free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/24\">",
"     24",
"    </a>",
"    ], and cytomegalovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, genetic factors may be involved in the development of vitiligo (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Association with autoimmune disease'",
"    </a>",
"    above). In addition to genes that affect immune function, a genome wide association study identified the TYR gene as a potential susceptibility locus for vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/15\">",
"     15",
"    </a>",
"    ]. TYR encodes tyrosinase, an enzyme that regulates melanin biosynthesis in melanocytes.",
"   </p>",
"   <p>",
"    Extrinsic factors also may play a role. Stress has been reported to precipitate vitiligo in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/26\">",
"     26",
"    </a>",
"    ], as has exposure to certain industrial chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/27\">",
"     27",
"    </a>",
"    ]. Although patients may associate sunburn with the onset of vitiligo, it is more likely that vitiliginous patches become noticeable after sunburn because they are more susceptible to sun exposure even before depigmentation is clinically apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/28\">",
"     28",
"    </a>",
"    ]. However, new patches of vitiligo also may occur in areas of trauma including sunburn (Koebner reaction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of onset of vitiligo is variable, but peaks in the second and third decades [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/3\">",
"     3",
"    </a>",
"    ]. Generalized vitiligo (vitiligo vulgaris) is the most common subtype, and is characterized by few to many widespread macules and patches that are often symmetrically placed (",
"    <a class=\"graphic graphic_picture graphicRef79198 \" href=\"UTD.htm?12/53/13139\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Generalized vitiligo frequently involves acral areas, skin surrounding body orifices (eg, mouth, eyes, nose), and extensor surfaces including interphalangeal joints, metacarpophalangeal, and metatarsophalangeal joints, elbows, and knees (",
"    <a class=\"graphic graphic_picture graphicRef74712 graphicRef51865 graphicRef53173 graphicRef62050 graphicRef63623 \" href=\"UTD.htm?38/50/39722\">",
"     picture 2A-E",
"    </a>",
"    ). Acrofacial vitiligo is the term for patients with vitiligo limited to acral and areas surrounding the orifices. Koebnerization may also occur with macules of vitiligo corresponding to places of injury, particularly in areas of rubbing such as shoulder straps, waistbands, and collar areas.",
"   </p>",
"   <p>",
"    The course usually is slowly progressive; 10 to 20 percent of patients may experience spontaneous repigmentation.",
"   </p>",
"   <p>",
"    Segmental vitiligo is a less common subtype that presents as unilateral depigmented macules and patches that completely or partially occur in a dermatomal distribution (",
"    <a class=\"graphic graphic_picture graphicRef72369 \" href=\"UTD.htm?35/34/36385\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/29\">",
"     29",
"    </a>",
"    ]. The disorder has an earlier age of onset than generalized vitiligo, and often spreads rapidly after initial appearance prior to stabilizing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/30\">",
"     30",
"    </a>",
"    ]. Segmental vitiligo is less commonly associated with other autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Studies have suggested that a neurogenic sympathetic abnormality or a disorder of cutaneous mosaicism may be contributing factors in the pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other subtypes of vitiligo include focal, mucosal, and universal vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/33\">",
"     33",
"    </a>",
"    ]. Focal vitiligo is characterized by depigmented macules located in an isolated area without a dermatomal distribution (",
"    <a class=\"graphic graphic_picture graphicRef70838 \" href=\"UTD.htm?6/17/6419\">",
"     picture 4",
"    </a>",
"    ). Mucosal vitiligo involves only the mucous membranes. Patients with universal vitiligo experience complete or almost complete depigmentation of the cutaneous surface (",
"    <a class=\"graphic graphic_picture graphicRef52435 \" href=\"UTD.htm?28/10/28837\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical variants of vitiligo can be seen with the above subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/32\">",
"     32",
"    </a>",
"    ]. Vitiligo ponctu&eacute; exhibits tiny, confetti-like depigmented macules. Inflammatory vitiligo presents with a peripheral erythematous rim. In trichrome vitiligo, three pigmentary hues are seen, with a visible gradient from depigmented to hypopigmented to normally pigmented skin. Quadrichrome vitiligo is trichrome vitiligo with the addition of perifollicular or marginal hyperpigmentation, and is more common in patients with darkly pigmented skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vitiligo is based upon the clinical presence of depigmented patches of skin. Examination with a Wood's lamp is useful for highlighting areas of pigment loss on lightly-pigmented patients. A full body skin examination should be performed in adult patients with new-onset vitiligo to exclude a melanoma-associated depigmentation.",
"   </p>",
"   <p>",
"    The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postinflammatory hypopigmentation &mdash; In this disorder, there is a decrease in pigmentation rather than absence, as in vitiligo. In addition, postinflammatory hypopigmentation is associated with a history of antecedent trauma or inflammation; one cause is liquid nitrogen therapy.",
"     </li>",
"     <li>",
"      Chemically induced depigmentation &mdash; Working with chemicals such as phenols may cause depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef72585 \" href=\"UTD.htm?19/27/19892\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tinea versicolor &mdash; Tinea versicolor is a superficial fungal infection that can present as hypopigmented (not depigmented) macules and patches with fine scale (",
"      <a class=\"graphic graphic_picture graphicRef73839 graphicRef72396 \" href=\"UTD.htm?26/43/27321\">",
"       picture 7A-B",
"      </a>",
"      ). Lesions may also be hyperpigmented or salmon colored. The upper trunk and shoulders are most commonly involved, but other sites may be affected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=see_link\">",
"       \"Tinea versicolor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pityriasis alba &mdash; Pityriasis alba is a mild form of eczematous dermatitis that presents with hypopigmented macules and small patches on the face, and less frequently on the upper extremities (",
"      <a class=\"graphic graphic_picture graphicRef60866 graphicRef73576 \" href=\"UTD.htm?14/55/15219\">",
"       picture 8A-B",
"      </a>",
"      ). Fine scale may be visible. The disorder is most common in children with an atopic history. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the patient with macular skin lesions\", section on 'Pityriasis alba'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic guttate hypomelanosis &mdash; A common skin condition characterized by multiple, small (&lt;6 mm), well-defined, depigmented macules; lesions are most frequently found on the forearms and anterior lower legs (",
"      <a class=\"graphic graphic_picture graphicRef61761 graphicRef67346 \" href=\"UTD.htm?12/48/13063\">",
"       picture 9A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nevus depigmentosus (achromic nevus) &mdash; This is a solitary, stable, hypopigmented patch that is present at birth or appears in early infancy (",
"      <a class=\"graphic graphic_picture graphicRef59799 \" href=\"UTD.htm?1/1/1041\">",
"       picture 10",
"      </a>",
"      ). Occasionally, nevus depigmentosus may present in a segmental or linear pattern.",
"     </li>",
"     <li>",
"      Hypomelanosis of Ito &mdash; Hypomelanosis of Ito (aka incontinentia pigmenti achromians) typically presents at birth or in early infancy with hypopigmented patches in a whorled or linear pattern that follows the lines of Blaschko (",
"      <a class=\"graphic graphic_picture graphicRef81308 \" href=\"UTD.htm?18/9/18576\">",
"       picture 11",
"      </a>",
"      ). Lesions are usually found on the trunk or extremities. Associated neurologic, ocular,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skeletal abnormalities may be present.",
"     </li>",
"     <li>",
"      Piebaldism &mdash; The lesions in piebaldism, a genetically inherited absence of pigment, involve patches of depigmented skin with hyperpigmented borders occurring principally on the mid-forehead, neck, anterior trunk, and mid-extremities (",
"      <a class=\"graphic graphic_picture graphicRef52591 graphicRef71514 \" href=\"UTD.htm?8/42/8870\">",
"       picture 12A-B",
"      </a>",
"      ). Normal pigmentation occurs on the hands, feet, back, shoulders, and hips. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H23#H23\">",
"       \"The genodermatoses\", section on 'Piebaldism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Morphea &mdash; In morphea, the texture of the skin is firm secondary to sclerotic changes in the dermis (",
"      <a class=\"graphic graphic_picture graphicRef60329 \" href=\"UTD.htm?13/0/13314\">",
"       picture 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Lichen sclerosus &mdash; The texture of the skin is thinned or inflamed (",
"      <a class=\"graphic graphic_picture graphicRef74154 \" href=\"UTD.htm?26/37/27216\">",
"       picture 14",
"      </a>",
"      ). There may be a follicular prominence, with complaints of burning, especially if the genitalia are involved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"       \"Vulvar lichen sclerosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leprosy &mdash; Areas of hypopigmentation will be anesthetic in leprosy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, hypopigmented patches resembling vitiligo may precede a diagnosis of cutaneous melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. In patients with melanoma, vitiligo-like depigmentation is thought to be a marker of an immune response against melanoma cells and may be an indicator of favorable prognosis in advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A skin biopsy is occasionally necessary to differentiate these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5455866\">",
"    <span class=\"h1\">",
"     SCREENING FOR AUTOIMMUNE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the frequency with which concomitant autoimmune disorders occur in patients with vitiligo, it may be reasonable to screen for selected diseases (eg, thyroid function, fasting blood glucose level), especially in children and young women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/14,39,40\">",
"     14,39,40",
"    </a>",
"    ]. European guidelines based upon expert consensus recommend the assessment of thyroid function (TSH, anti-thyroperoxidase, antithyroglobulin antibodies) in patients with vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/41\">",
"     41",
"    </a>",
"    ]. They also recommend the measurement of additional antibodies only if patient&rsquo;s history, family history, or physical examination suggests other autoimmune diseases. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is necessary and should begin early when the disease is emotionally and physically disfiguring, which is more likely in dark-skinned individuals and in children, or when acral areas are involved. In addition to therapies designed to induce repigmentation, use of sunscreens, particularly in individuals with light skin, minimizes tanning, thereby limiting the contrast between diseased and normal skin. Makeups (eg, Covermark, Dermablend) may help camouflage depigmented areas in lighter-skinned patients, as can stains with dihydroxyacetone (eg, Vitadye, Chromelin).",
"   </p>",
"   <p>",
"    Repigmentation therapies include corticosteroids, calcineurin inhibitors, ultraviolet light, and surgery. Depigmentation of normal skin is considered only rarely in patients with widespread vitiligo because of the total loss of sun protection, cultural factors, and the permanent nature of the treatment.",
"   </p>",
"   <p>",
"    Many studies of treatments for vitiligo are of poor quality and so evidence is limited, particularly for the long-term benefits and safety of therapies. A systematic review concluded that for short-term benefits there is moderate quality evidence for topical corticosteroids and limited to moderate quality evidence for ultraviolet light therapy used alone or in combination with other topical or oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitiligo can lead to significant psychological distress. Asking patients about how the disease affects their lives can help with managing psychological impact and may increase adherence to therapies for vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are frequently the first treatment of choice for patients with limited disease (covering less than 10 percent of the body) that does not involve the face [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/44\">",
"     44",
"    </a>",
"    ]. In a meta-analysis, the pooled odds ratio of success in randomized, controlled studies with topical class III corticosteroids compared to placebo was 14.3; among patient series, approximately 55 percent of patients with localized vitiligo responded to class III and IV topical corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults and patients over the age of 12 should be treated with mid-potency (class III or IV) topical corticosteroids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate ointment or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    cream once a day for four to six months (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). Children under the age of 12 should use lower potency (class V) preparations such as fluticasone propionate cream or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"     desonide",
"    </a>",
"    0.05 percent cream once a day for four months (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). When higher potency preparations are used to treat vitiligo in children, there is a substantial risk of systemic absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/46\">",
"     46",
"    </a>",
"    ]. If repigmentation occurs, continue treating until no further response is noted. Patients should be followed every four weeks during therapy to monitor for signs of corticosteroid-induced skin atrophy.",
"   </p>",
"   <p>",
"    Oral glucocorticoids have been successfully used in patients with progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Referral to a dermatologist is warranted for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical calcineurin inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    ) may be an effective therapy for vitiligo; however, most of the evidence of their use comes from small case series and uncontrolled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/11,49-53\">",
"     11,49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one randomized trial, 20 children were treated twice daily for two months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate 0.05 percent to one lesion and with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1 percent to a similar lesion in a blinded fashion; 90 percent of patients experienced some repigmentation, and the mean percentage of lesion repigmentation was similar with tacrolimus and clobetasol (41.3 versus 49.3 percent, p-value not calculated in article) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/54\">",
"     54",
"    </a>",
"    ]. There are no published placebo-controlled trials of treatment with topical calcineurin inhibitors alone for vitiligo. A placebo-controlled trial in six patients who were all treated in combination with excimer-laser therapy found a higher success rate with topical tacrolimus than with a topical placebo (50 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/55\">",
"     55",
"    </a>",
"    ]; however, a study in nine patients suggested that topical tacrolimus monotherapy (without UV light exposure) was ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2005, the Unites States Food and Drug Administration (FDA) issued an alert about a possible link between topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and cases of lymphoma and skin cancer in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/57\">",
"     57",
"    </a>",
"    ], and in 2006 placed a \"black box\" warning on the prescribing information for these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/58\">",
"     58",
"    </a>",
"    ]. No definite causal relationship has been established; however, the FDA recommended that these agents only be used as second-line agents for atopic dermatitis. If these agents are used for the treatment of vitiligo, it would be reasonable to follow the additional safety recommendations made by the FDA for their use in atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Topical calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike topical corticosteroids, topical calcineurin inhibitors do not cause skin atrophy. After topical corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    could be a reasonable therapeutic agent to try for vitiligo affecting areas at high risk of atrophy, such as the face, taking into account the cautions and potential study limitations discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ultraviolet light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photochemotherapy with topical or oral psoralens plus ultraviolet A radiation (PUVA), or ultraviolet B (UVB) radiation phototherapy is used in patients with more extensive vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/44,59\">",
"     44,59",
"    </a>",
"    ]. In the meta-analysis cited above, both treatments were similarly effective in patients with generalized vitiligo (51 and 57 percent for PUVA and UVB therapy, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/45\">",
"     45",
"    </a>",
"    ]. PUVA was associated with more side effects, leading the authors to favor UVB therapy.",
"   </p>",
"   <p>",
"    Patients must be referred to a dermatologist for ultraviolet radiation therapy. A total of 75 to 150 treatments (eg, three times per week for 6 to 12 months) may be necessary.",
"   </p>",
"   <p>",
"    Narrowband UVB is a newer treatment that does not require photosensitizing agents and may be more effective for vitiligo than traditional UVB or PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. A small randomized trial that compared narrowband UVB with PUVA in 56 patients with vitiligo found a nonstatistically significant greater reduction in the median surface area of vitiligo in patients treated with narrowband UVB (61 versus 23 percent); the color match of repigmented skin was also better with narrowband UVB than with PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/63\">",
"     63",
"    </a>",
"    ]. In another randomized trial including 53 patients, repigmentation of 51 to 75 percent was achieved in 12 percent of patients in the narrowband UVB group and 30 percent of patients in the PUVA group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/14\">",
"     14",
"    </a>",
"    ]. Adverse effects (eg, pruritus, hyperpigmentation, nausea) were more common in the PUVA group than in the narrowband UVB group (57 versus 7 percent).",
"   </p>",
"   <p>",
"    Several factors can lessen the efficacy of narrowband UVB. Lesions in acral sites are less likely to respond well to treatment than lesions on the face, trunk, or limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, segmental vitiligo is less responsive to treatment. Long-standing lesions may also exhibit a lower rate of success in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The long-term efficacy and safety of narrowband UVB need further study in larger randomized trials before it becomes the standard method of administering UV light for vitiligo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179038331\">",
"    <span class=\"h3\">",
"     Combined with calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with UVB and calcineurin inhibitors has been tried to improve or accelerate repigmentation in patients with vitiligo. A prospective non-randomized left-right comparison study noted improvement in repigmentation with combination therapy, but randomized trials have had mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Current evidence is insufficient to recommend for or against this therapy. The risks (carcinogenicity, photodamage) and potential benefits for individual patients must be weighed on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Excimer laser/lamp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 308 nm excimer laser emits a wavelength of ultraviolet light close to that of narrowband UVB (311 nm). The excimer laser is an effective treatment for vitiligo, although impractical for the treatment of patients with widespread or large lesions since it is delivered to small, targeted areas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/70-74\">",
"     70-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small randomized investigator-blinded trial comparing the efficacy of targeted UVB therapy utilizing a 308 nm monochromatic excimer lamp versus narrowband UVB phototherapy revealed superior outcomes for patients treated with the excimer lamp [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/75\">",
"     75",
"    </a>",
"    ]. In another study of 14 patients with evolving vitiligo, symmetrical lesions were assigned by left-right randomization to treatment with 308 nm excimer lamp or laser (three times per week for a maximum of 20 treatments) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/76\">",
"     76",
"    </a>",
"    ]. At the end of the study, there was no difference in the repigmentation rate between the two treatment modalities.",
"   </p>",
"   <p>",
"    The addition of topical therapies can be useful. A small randomized controlled trial examined the benefit of the use of the excimer laser plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    17-butyrate cream in patients with vitiligo of the face and neck who had failed treatment with narrowband UVB or topical corticosteroid monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/77\">",
"     77",
"    </a>",
"    ]. After twelve weeks, a greater than 75 percent reduction in vitiligo lesions was seen in 43 percent of patients receiving treatment with the excimer laser and topical hydrocortisone 17-butyrate cream compared with only 17 percent of patients receiving treatment with the excimer laser alone. The combination of the excimer laser with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has also led to improved results for lesions in traditionally UV-resistant areas (bony prominences and distal extremities) compared to excimer laser monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Topical vitamin D analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical vitamin D analogs inhibit T cell activation and promote melanocyte maturation and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/79\">",
"     79",
"    </a>",
"    ]. Topical calcipotriol (calcipotriene) and topical tacalcitol have been utilized in treatment regimens for vitiligo. The benefit of these treatments is controversial.",
"   </p>",
"   <p>",
"    Most studies have focused on the combination of topical vitamin D analogs with exposure to sunlight or therapeutic ultraviolet light. Small studies have reported improved results with combination treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/80-88\">",
"     80-88",
"    </a>",
"    ]. Conflicting findings also exist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/62,89-92\">",
"     62,89-92",
"    </a>",
"    ], including a randomized, double-blind trial of 80 patients that showed no additional benefit of topical tacalcitol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical vitamin D analogs have also been used in combination with topical glucocorticoids. Combined treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate led to faster repigmentation and better stability of treatment effect compared to monotherapy with either agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/94\">",
"     94",
"    </a>",
"    ]. A combination of calcipotriene and topical corticosteroids led to improvement in patients who failed treatment with topical corticosteroids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/95\">",
"     95",
"    </a>",
"    ]. Few studies have evaluated the efficacy of topical vitamin D analogs as monotherapy, and results have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/96-98\">",
"     96-98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pseudocatalase cream",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study showed that patients with vitiligo have low catalase levels in their epidermis in association with high levels of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . A topical pseudocatalase cream with or without ultraviolet light therapy, utilized twice a day, may remove epidermal hydrogen peroxide and induce repigmentation in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]; however, the cream is not very stable and is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skin grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be warranted when medical therapies fail; surgery can also be used in combination with medical therapy. Autologous minigrafting techniques, with or without light (PUVA) therapy, and melanocyte-keratinocyte transplantation have been used in recalcitrant cases, although they are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Depigmentation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depigmentation with 20% monobenzyl ether of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    may be an option if vitiligo affects more than 50 percent of the face or body and is recalcitrant to therapy. Patients should be advised that depigmentation is permanent, although cases of repigmentation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. The major side effect is contact dermatitis that typically responds to topical corticosteroids. Patients also experience sun sensitivity after depigmentation. Consultation with a dermatologist is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other therapies have been tried in patients with vitiligo. Examples include tar emulsions and immunomodulators such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and levamisole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/106\">",
"     106",
"    </a>",
"    ]. Vitamins such as vitamin B12 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    plus sunlight have been reported to be effective in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/107\">",
"     107",
"    </a>",
"    ]. Oral ginkgo biloba has shown efficacy in a randomized trial of patients with limited, slowly spreading vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21193/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938502\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitiligo is an acquired skin depigmentation occurring in approximately 1 percent of the population worldwide. It results from an autoimmune process directed against the melanocytes. Vitiligo is frequently associated with other autoimmune disorders, including autoimmune thyroid disease, pernicious anemia, systemic lupus erythematosus, and Addison disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized vitiligo (vitiligo vulgaris) is the most common subtype, and is characterized by widespread macules and patches that are often symmetrically distributed (",
"      <a class=\"graphic graphic_picture graphicRef79198 \" href=\"UTD.htm?12/53/13139\">",
"       picture 1",
"      </a>",
"      ). Acrofacial vitiligo typically involves areas surrounding body orifices and extensor surfaces (",
"      <a class=\"graphic graphic_picture graphicRef74712 graphicRef51865 graphicRef53173 graphicRef62050 graphicRef63623 \" href=\"UTD.htm?38/50/39722\">",
"       picture 2A-E",
"      </a>",
"      ). Other subtypes include segmental (",
"      <a class=\"graphic graphic_picture graphicRef72369 \" href=\"UTD.htm?35/34/36385\">",
"       picture 3",
"      </a>",
"      ), focal (",
"      <a class=\"graphic graphic_picture graphicRef74712 \" href=\"UTD.htm?34/31/35312\">",
"       picture 2A",
"      </a>",
"      ), mucosal (",
"      <a class=\"graphic graphic_picture graphicRef51865 \" href=\"UTD.htm?11/58/12196\">",
"       picture 2B",
"      </a>",
"      ), and universal vitiligo (",
"      <a class=\"graphic graphic_picture graphicRef52435 \" href=\"UTD.htm?28/10/28837\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of vitiligo is based upon the clinical presence of depigmented patches of skin. Examination with a Wood lamp is useful for highlighting areas of pigment loss on light skinned patients. Given the frequency with which concomitant autoimmune disorders occur in patients with vitiligo, it is reasonable to screen for selected diseases (eg, thyroid function, CBC, and fasting blood glucose level), especially in children and young women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of vitiligo is based upon repigmentation therapies, which include topical and oral corticosteroids, topical calcineurin inhibitors, ultraviolet light (PUVA and narrowband UVB), and skin grafting techniques. Depigmentation of normal skin is considered only rarely in patients with widespread vitiligo because of the permanent nature of the treatment and total loss of sun protection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/1\">",
"      Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/2\">",
"      Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/3\">",
"      Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol 1999; 26:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/4\">",
"      van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/5\">",
"      Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/6\">",
"      Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/7\">",
"      Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/8\">",
"      Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/9\">",
"      Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/10\">",
"      Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/11\">",
"      Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/12\">",
"      Basak PY, Adiloglu AK, Ceyhan AM, et al. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009; 60:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/13\">",
"      Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/14\">",
"      Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol 2012; 167:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/15\">",
"      Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/16\">",
"      Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010; 42:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/17\">",
"      Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/18\">",
"      Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol 2013; 133:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/19\">",
"      Trence DL, Morley JE, Handwerger BS. Polyglandular autoimmune syndromes. Am J Med 1984; 77:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/20\">",
"      Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/21\">",
"      Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/22\">",
"      Im S, Hann SK, Kim HI, et al. Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol 1994; 33:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/23\">",
"      Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/24\">",
"      Schallreuter KU, Wood JM. Free radical reduction in the human epidermis. Free Radic Biol Med 1989; 6:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/25\">",
"      Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996; 35:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/26\">",
"      Papadopoulos L, Bor R, Legg C, Hawk JL. Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol 1998; 23:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/27\">",
"      O'Sullivan JJ, Stevenson CJ. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol. Br J Ind Med 1981; 38:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/28\">",
"      Nordlund JJ, Lerner AB. Vitiligo. It is important. Arch Dermatol 1982; 118:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/29\">",
"      Ta&iuml;eb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/30\">",
"      Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996; 35:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/31\">",
"      Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol 2010; 62:945.",
"     </a>",
"    </li>",
"    <li>",
"     Halder RM, Taliaferro SJ. Vitiligo. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008.",
"    </li>",
"    <li>",
"     Ortonne J. Vitiligo and other disorders of hypopigmentation. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/34\">",
"      Cho EA, Lee MA, Kang H, et al. Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin. Ann Dermatol 2009; 21:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/35\">",
"      Onsun N, B&uuml;y&uuml;kbabani N, Ummetolu O, Cebeci F. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo. J Dermatol 2009; 36:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/36\">",
"      Redondo P, Del Olmo J. Images in clinical medicine. Vitiligo and cutaneous melanoma. N Engl J Med 2008; 359:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/37\">",
"      Wang JR, Yu KJ, Juan WH, Yang CH. Metastatic malignant melanoma associated with vitiligo-like depigmentation. Clin Exp Dermatol 2009; 34:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/38\">",
"      Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/39\">",
"      Daneshpazhooh M, Mostofizadeh G M, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/40\">",
"      Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005; 53:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/41\">",
"      Taieb A, Alomar A, B&ouml;hm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/42\">",
"      Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev 2010; :CD003263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/43\">",
"      Ongenae K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/44\">",
"      Njoo MD, Westerhof W, Bos JD, Bossuyt PM. The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol 1999; 135:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/45\">",
"      Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998; 134:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/46\">",
"      Kwinter J, Pelletier J, Khambalia A, Pope E. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol 2007; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/47\">",
"      Seiter S, Ugurel S, Tilgen W, Reinhold U. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000; 39:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/48\">",
"      Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/49\">",
"      Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/50\">",
"      Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/51\">",
"      Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol 2003; 139:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/52\">",
"      Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/53\">",
"      Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/54\">",
"      Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/55\">",
"      Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/56\">",
"      Ostovari N, Passeron T, Lacour JP, Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142:252.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/advisory/elidel_protopic.htm (Accessed on March 10, 2005).",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topics/news/2006/NEW01299.html (Accessed on January 20, 2016).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/59\">",
"      Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/60\">",
"      Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol 2005; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/61\">",
"      Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/62\">",
"      Hartmann A, Lurz C, Hamm H, et al. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005; 44:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/63\">",
"      Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 2007; 143:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/64\">",
"      Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed 2006; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/65\">",
"      Brazzelli V, Antoninetti M, Palazzini S, et al. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol 2007; 21:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/66\">",
"      Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009; 20:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/67\">",
"      Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/68\">",
"      Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed 2010; 26:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/69\">",
"      Nordal EJ, Guleng GE, R&ouml;nnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol 2011; 25:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/70\">",
"      Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002; 46:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/71\">",
"      Esposito M, Soda R, Costanzo A, Chimenti S. Treatment of vitiligo with the 308 nm excimer laser. Clin Exp Dermatol 2004; 29:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/72\">",
"      Hadi SM, Spencer JM, Lebwohl M. The use of the 308-nm excimer laser for the treatment of vitiligo. Dermatol Surg 2004; 30:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/73\">",
"      Hofer A, Hassan AS, Legat FJ, et al. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol 2005; 152:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/74\">",
"      Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. J Am Acad Dermatol 2009; 60:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/75\">",
"      Casacci M, Thomas P, Pacifico A, et al. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo--a multicentre controlled study. J Eur Acad Dermatol Venereol 2007; 21:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/76\">",
"      Shi Q, Li K, Fu J, et al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo--a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed 2013; 29:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/77\">",
"      Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008; 159:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/78\">",
"      Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/79\">",
"      Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008; 9:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/80\">",
"      Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001; 145:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/81\">",
"      Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/82\">",
"      Lu-yan T, Wen-wen F, Lei-hong X, et al. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2006; 22:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/83\">",
"      Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/84\">",
"      Amano H, Abe M, Ishikawa O. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 2008; 25:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/85\">",
"      Katayama I, Ashida M, Maeda A, et al. Open trial of topical tacalcitol [1 alpha 24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003; 13:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/86\">",
"      Yal&ccedil;in B, Sahin S, B&uuml;k&uuml;lmez G, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol 2001; 44:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/87\">",
"      Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2004; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/88\">",
"      Leone G, Pacifico A, Iacovelli P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006; 31:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/89\">",
"      Arca E, Tatan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006; 33:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/90\">",
"      Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed 2005; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/91\">",
"      Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/92\">",
"      Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol 2003; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/93\">",
"      Rodr&iacute;guez-Mart&iacute;n M, Garc&iacute;a Bust&iacute;nduy M, S&aacute;ez Rodr&iacute;guez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009; 160:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/94\">",
"      Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006; 20:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/95\">",
"      Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004; 21:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/96\">",
"      Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 1999; 16:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/97\">",
"      Chiav&eacute;rini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/98\">",
"      Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/99\">",
"      Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol 1999; 12:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/100\">",
"      Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/101\">",
"      Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol 1988; 124:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/102\">",
"      Gupta S, Kumar B. Epidermal grafting in vitiligo: influence of age, site of lesion, and type of disease on outcome. J Am Acad Dermatol 2003; 49:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/103\">",
"      Huggins RH, Henderson MD, Mulekar SV, et al. Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States. J Am Acad Dermatol 2012; 66:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/104\">",
"      Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000; 42:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/105\">",
"      Oakley AM. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone. Australas J Dermatol 1996; 37:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/106\">",
"      Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994; 33:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/107\">",
"      Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol 1997; 77:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21193/abstract/108\">",
"      Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2003; 28:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5578 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21193=[""].join("\n");
var outline_f20_44_21193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5938502\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Humoral immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Association with autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5455866\">",
"      SCREENING FOR AUTOIMMUNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ultraviolet light",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179038331\">",
"      - Combined with calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Excimer laser/lamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Topical vitamin D analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pseudocatalase cream",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skin grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Depigmentation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938502\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5578|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/53/13139\" title=\"picture 1\">",
"      Vitiligo generalized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/31/35312\" title=\"picture 2A\">",
"      Vitiligo - elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/58/12196\" title=\"picture 2B\">",
"      Vitiligo - lips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/16/23810\" title=\"picture 2C\">",
"      Vitiligo - periocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/17/23825\" title=\"picture 2D\">",
"      Vitiligo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/54/37730\" title=\"picture 2E\">",
"      Vitiligo - hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/34/36385\" title=\"picture 3\">",
"      Vitiligo segmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/17/6419\" title=\"picture 4\">",
"      Vitiligo focal leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/10/28837\" title=\"picture 5\">",
"      Vitiligo universal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19892\" title=\"picture 6\">",
"      Chemical depigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/9/20630\" title=\"picture 7A\">",
"      Tinea versicolor shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/23/19827\" title=\"picture 7B\">",
"      Tinea versicolor back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/30/33262\" title=\"picture 8A\">",
"      Pityriasis alba 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/29/22992\" title=\"picture 8B\">",
"      Pityriasis alba 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/22/11618\" title=\"picture 9A\">",
"      Idiopathic guttate hypomelanosis - thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/52/30529\" title=\"picture 9B\">",
"      Idiopathic guttate hypomelanosis - arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/1/1041\" title=\"picture 10\">",
"      Nevus depigmentosus - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/9/18576\" title=\"picture 11\">",
"      Hypomelanosis of Ito - trunk and arms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/17/20753\" title=\"picture 12A\">",
"      Piebaldism - forelock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/21/21840\" title=\"picture 12B\">",
"      Piebaldism - trunk and extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/0/13314\" title=\"picture 13\">",
"      Morphea - hypopigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/37/27216\" title=\"picture 14\">",
"      Lichen sclerosus - trunk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=related_link\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21194="Acute treatment of migraine in adults";
var content_f20_44_21194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute treatment of migraine in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Ashraf Sabahat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/44/21194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/44/21194/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/44/21194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a common disorder, with a one-year prevalence rate in Americans of approximately 13 percent (18 percent of women and 6 to 7 percent of men) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute treatment of migraine in adults is reviewed here. Preventive treatment of migraine in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, and diagnosis of the migraine are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A headache diary helps to identify factors that precipitate migraine so they can be avoided (",
"    <a class=\"graphic graphic_form graphicRef64049 \" href=\"UTD.htm?18/16/18688\">",
"     form 1",
"    </a>",
"    ). However, most migraine sufferers still require pharmacologic treatment.",
"   </p>",
"   <p>",
"    The abortive (symptomatic) therapy of migraine ranges from the use of simple analgesics such as nonsteroidal antiinflammatory drugs (NSAIDs) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    to triptans or the less commonly used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    . Abortive treatments are usually more effective if they are given early in the course of the headache; a large single dose tends to work better than repetitive small doses. Many oral agents are ineffective because of poor absorption secondary to migraine-induced gastric stasis.",
"   </p>",
"   <p>",
"    The American Academy of Neurology, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine, and four other groups formed a consortium (the US Headache Consortium) that evaluated the optimal approach to migraine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition to a specific review of individual medications, the consortium made the following general recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educate migraine sufferers about their condition and its treatment and encourage them to participate in their own management.",
"     </li>",
"     <li>",
"      Use migraine specific agents (eg, triptans, DHE,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      ) in patients with more severe migraine and in those whose headaches respond poorly to NSAIDs or combination analgesics.",
"     </li>",
"     <li>",
"      Select a non-oral route of administration for patients whose migraines present early with significant nausea or vomiting.",
"     </li>",
"     <li>",
"      Consider a self-administered rescue medication for patients with severe migraines that do not respond well to other treatments.",
"     </li>",
"     <li>",
"      Guard against medication overuse headache by using prophylactic medications in patients with frequent headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic headache related to medication overuse (analgesic rebound headache) is a common disorder with significant morbidity. Almost any acute headache medication can be implicated, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , butalbital-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -caffeine (Fiorinal), and aspirin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/4\">",
"     4",
"    </a>",
"    ]. In one study, patients with medication overuse headache were using analgesics (35 percent), ergots (22 percent), opioids (12.5 percent), triptans (2.7 percent), and different combinations (27.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to prevent the development of medication overuse headache (MOH), acute medications should be limited to no more than 10 days per month, and preventive therapies should be used as the mainstay in patients with frequent headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MILD ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with migraine have an optimal response with mild analgesics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , other nonsteroidal antiinflammatory drugs (NSAIDs), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal anti-inflammatory drugs (NSAIDs) with reported efficacy in randomized, placebo-controlled trials of migraine therapy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (650 to 1000 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/6-8\">",
"     6-8",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (400 to 1200 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/9,10\">",
"     9,10",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (750 to 1250 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/11,12\">",
"     11,12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    (50 to 100 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/13\">",
"     13",
"    </a>",
"    ], diclofenac epolamine (65 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/14\">",
"     14",
"    </a>",
"    ], and tolfenamic acid (200 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/15\">",
"     15",
"    </a>",
"    ]. Some of these studies are limited by varying outcome measures and definitions of migraine, but all NSAIDs may be beneficial in patients who have migraine, with or without aura.",
"   </p>",
"   <p>",
"    Although the data are limited, benefit may be seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    as abortive therapy for migraine. It is a potent NSAID that is also available in suppository form, which may be helpful for nauseated patients. Indomethacin suppositories contain 50 mg of the drug; the suppositories may be cut into halves or thirds for patients with recurrent attacks.",
"   </p>",
"   <p>",
"    There are no studies comparing the relative efficacy of different NSAIDs. If one NSAID is ineffective, a different drug may be tried. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is an effective abortive agent in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/16\">",
"     16",
"    </a>",
"    ]. This was illustrated in a population-based randomized, placebo-controlled trial of patients with self-reported migraine, which found acetaminophen at a dose of 1000 mg to be highly effective for treating pain, functional disability, photophobia, and phonophobia, although the study excluded patients with severe symptoms requiring bed rest or associated with vomiting more than 20 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    can be used in combination with NSAIDs. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/1/30743?source=see_link\">",
"     acetaminophen-aspirin-caffeine",
"    </a>",
"    (Excedrin, 2 extra strength tablets) was found to alleviate headaches in patients with uncomplicated migraine in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRIPTANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serotonin",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    agonists (triptans) are considered to be \"specific\" therapies for acute migraine since, in contrast to analgesics, they act at the pathophysiologic mechanism of the headache [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the triptans inhibit the release of vasoactive peptides, promote vasoconstriction, and block pain pathways in the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/19\">",
"     19",
"    </a>",
"    ]. Triptans inhibit transmission in the trigeminal nucleus caudalis, thereby blocking afferent input to second order neurons; this effect is probably mediated by reducing the levels of calcitonin gene related peptide (CGRP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triptans may also activate 5-HT",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptors in descending brainstem pain modulating pathways and thereby inhibit dural nociception [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An advantage of the serotonin agonists over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    is their availability in oral preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/21\">",
"     21",
"    </a>",
"    ]. Many patients have been able to use these drugs either at home or in the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/22\">",
"     22",
"    </a>",
"    ] without significant problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Preparations and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available triptans include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"     naratriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"     rizatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"     almotriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"     eletriptan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"     frovatriptan",
"    </a>",
"    . Sumatriptan can be given as a subcutaneous injection (usually administered by autoinjector in the thigh), as a nasal spray, or orally. Zolmitriptan is also available for both nasal and oral use. The others are available for oral use only. The cost of the oral preparations is similar (average wholesale price $15 to $19 per attack). Intranasal sumatriptan and zolmitriptan are more expensive (average wholesale price $24 per attack), as is subcutaneous sumatriptan ($58 per attack).",
"   </p>",
"   <p>",
"    A number of randomized, controlled trials and systematic reviews have found all of the triptans to be effective for the treatment of acute migraine. The range of findings is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"       Eletriptan",
"      </a>",
"      &mdash; In a meta-analysis of six randomized, controlled trials of eletriptan involving 3224 patients, eletriptan at doses of 20, 40, and 80 mg was significantly better than placebo for all main outcomes (including headache response at one and two hours and sustained relief over 24 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/23\">",
"       23",
"      </a>",
"      ]. Pain relief was dose dependent, with the 80 mg dose providing statistically significant greater pain relief than 40 mg at two and 24 hours. The drug was well tolerated and caused no major harm. The incidence of minor side effects was also dose related, but all adverse effects were transient and reversible. Eletriptan is not available in 80 mg tablets in the United States, and 40 mg is recommended for most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"       Naratriptan",
"      </a>",
"      &mdash; At least three randomized trials have found that naratriptan significantly improves acute migraine relief compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. In one of the studies, a dose of 2.5 mg was most effective in producing headache relief at four hours, with an adverse event rate similar to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/26\">",
"       26",
"      </a>",
"      ]. Adverse events did not appear to be dose related.",
"      <br/>",
"      <br/>",
"      In a second study, patients who did not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      50 mg with a first attack had a significantly superior response to naratriptan 2.5 mg compared with placebo during a second migraine attack one week later, suggesting that patients who do not respond to one triptan may respond to another [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/27\">",
"       27",
"      </a>",
"      ]. One problem with this study is that the 50 mg dose of sumatriptan used is often suboptimal [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/28\">",
"       28",
"      </a>",
"      ]. On the other hand, it is worthwhile to try another triptan if the response is not optimal.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"       Rizatriptan",
"      </a>",
"      &mdash; The efficacy of rizatriptan for acute migraine has been demonstrated in a systematic review of seven randomized, placebo-controlled studies involving 3528 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/29\">",
"       29",
"      </a>",
"      ]. Significant benefit of rizatriptan compared with placebo was shown for both the 5 and 10 mg dose of rizatriptan for all five main efficacy outcomes (ranging from relief at 1 to 24 hours). The 10 mg dose was more effective than 5 mg. The most common adverse effects were dizziness,",
"      <span class=\"nowrap\">",
"       asthenia/fatigue,",
"      </span>",
"      nausea, and somnolence; in one study these effects were dose dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       Sumatriptan",
"      </a>",
"      &mdash; All three preparations of sumatriptan &ndash; subcutaneous, oral, and intranasal &ndash; have proven efficacy in randomized, placebo-controlled trials of acute migraine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. In a systematic review (search date 1997) that included 36 randomized trials and 7437 patients, subcutaneous sumatriptan (6 mg) was significantly more effective than oral sumatriptan (100 mg), but it was associated with more adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/34\">",
"       34",
"      </a>",
"      ]. Subcutaneous sumatriptan had the fastest onset of action. Intranasal sumatriptan (typically one insufflation of sumatriptan 20 mg, repeated at two hours if necessary) had a faster onset of action than oral, and fewer side effects than injectable. In one trial of subcutaneous sumatriptan in 639 patients, administration of a second dose of the drug 60 minutes after the first in those who did not respond well initially provided little additional benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/35\">",
"       35",
"      </a>",
"      ]. In a second report, initial administration of 50 mg of oral sumatriptan was as effective as 100 mg, suggesting that the lower dose provided the best combination of efficacy and tolerability; either 50 or 100 mg was more effective than a 25 mg dose [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Common side effects of subcutaneous sumatriptan include an injection site reaction, chest pressure or heaviness, flushing, weakness, drowsiness, dizziness, malaise, a feeling of warmth, and paresthesias. Most of these reactions occur soon after the injection and resolve spontaneously within 30 minutes. There have been rare reports of myocardial infarction and sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/37\">",
"       37",
"      </a>",
"      ], possibly due to coronary artery constriction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/38\">",
"       38",
"      </a>",
"      ]. The most common side effect of intranasal sumatriptan is an unpleasant taste.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       Zolmitriptan",
"      </a>",
"      &mdash; At least two large randomized, placebo-controlled studies have proven the efficacy of zolmitriptan for acute migraine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In one study of 1000 patients, four doses of zolmitriptan (1, 2.5, 5, and 10 mg) were compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/39\">",
"       39",
"      </a>",
"      ]. There was a dose-response relationship in terms of both efficacy and adverse effects; 2.5 mg appeared to be the optimal starting dose. The most common side effects included nausea, dizziness, somnolence, paresthesia, fatigue, and tightness in the throat or chest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of triptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few trials have compared the triptans head to head, making it difficult to decide whether to use one versus another. A meta-analysis of 53 clinical trials of the oral serotonin agonists that included over 24,000 patients concluded that all of the available oral drugs are effective and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/41\">",
"     41",
"    </a>",
"    ]. The highest likelihood of consistent success was found with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"     rizatriptan",
"    </a>",
"    (10 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"     eletriptan",
"    </a>",
"    (80 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"     almotriptan",
"    </a>",
"    (12.5 mg).",
"   </p>",
"   <p>",
"    It should be noted that this meta-analysis was performed prior to the release of reformulated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    tablets in early 2004. The new tablets dissolve much faster than conventional tablets, which may allow the drug to be absorbed into the blood stream more rapidly. However, there is as yet no clinical trial data regarding the efficacy of the new sumatriptan tablets versus other triptans.",
"   </p>",
"   <p>",
"    The choice of serotonin agonist should be individualized; different pharmacologic properties and delivery routes may help guide the choice.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     Sumatriptan",
"    </a>",
"    offers the most options for drug delivery.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"     Naratriptan",
"    </a>",
"    has been reported to have the lowest recurrence rate of all the serotonin agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/26\">",
"     26",
"    </a>",
"    ], but this low recurrence rate is likely an artifact that is due to its low initial response rate compared with other triptans (ie, in order for a headache to recur, it must first have significantly improved). In addition, naratriptan has the slowest onset of action among the triptans.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"     Rizatriptan",
"    </a>",
"    has the fastest onset of action; the dose must be adjusted downward in patients who take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    since propranolol increases rizatriptan levels by 70 percent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"     Almotriptan",
"    </a>",
"    was reported to have fewer side effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    in one head-to-head comparison study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/42\">",
"     42",
"    </a>",
"    ], although the rate of adverse event-related withdrawal from one-year treatment extension trials for almotriptan is similar to that of the other triptans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients who do not respond well to one triptan may respond to another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factors predicting response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt treatment of migraine attacks has been considered important to successful acute therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/28,44,45\">",
"     28,44,45",
"    </a>",
"    ], but few rigorous studies have examined the factors that may influence the probability of a good response to triptan therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, placebo-controlled trial that evaluated 403 patients with migraine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"       almotriptan",
"      </a>",
"      12.5 mg was effective whether started when headache was early and mild, or started when headache was moderate to severe [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/46\">",
"       46",
"      </a>",
"      ]. When treatment was initiated while headache intensity was mild and within one hour of onset, a significantly greater proportion of patients were pain-free at two hours with almotriptan than with placebo (49 versus 25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/46\">",
"       46",
"      </a>",
"      ]. Similarly, when treatment was started when headache intensity was moderate to severe, almotriptan remained significantly better than placebo on the same outcome measure (40 versus 15 percent).",
"     </li>",
"     <li>",
"      Another study analyzed a database of 130,000 migraine attacks in 28,000 patients with migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/47\">",
"       47",
"      </a>",
"      ]. Pretreatment pain severity was the strongest predictor of headache relief (mild or no pain) and pain-free response two hours after taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      , with lower baseline severity predicting a better response. The resistance of severe pain to triptan therapy found in this study may be due to the development of central sensitization during the attack, which is thought to counteract analgesic and triptan therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients susceptible to cutaneous allodynia (the perception of pain produced by innocuous stimulation of normal skin), limited data suggest that triptans are less effective once allodynia is established during migraine attacks. In a study of 31 patients, triptan treatment resulted in complete pain relief by two hours in only 15 percent of 34 allodynic attacks versus 97 percent of 27 non-allodynic attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/48\">",
"     48",
"    </a>",
"    ]. The authors concluded that patients who develop allodynia, which takes one to four hours to establish [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/49\">",
"     49",
"    </a>",
"    ], should take triptans as early as possible in a migraine attack. Conversely, patients who never develop allodynia can benefit from triptan therapy at any time during an attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations to use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triptans have proven to be safe and effective for most patients with migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/50\">",
"     50",
"    </a>",
"    ]. In a cohort study of 63,575 patients with migraine, 13,664 of whom were treated with a triptan, there was no association between triptan prescription and stroke, other cardiovascular events, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/51\">",
"     51",
"    </a>",
"    ]. However, it should be noted that in this cohort triptans were prescribed to those at less risk of these events. Similarly, a smaller case-control study found that triptan overuse was not associated with an increased risk of cerebrovascular, cardiovascular, or ischemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on limited evidence, it is still recommended that triptans be avoided in patients with familial hemiplegic migraine, basilar migraine, ischemic stroke, ischemic heart disease, Prinzmetal's angina, uncontrolled hypertension, and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/53\">",
"     53",
"    </a>",
"    ]. It may be prudent to give the first dose of the drug under medical supervision for patients with risk factors but no known coronary heart disease (including men over the age of 40 and postmenopausal women, and patients with controlled vascular risk factors such as diabetes mellitus, hypercholesterolemia, and hypertension).",
"   </p>",
"   <p>",
"    Combination with monoamine oxidase inhibitors is contraindicated with triptans other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"     eletriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"     frovatriptan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"     naratriptan",
"    </a>",
"    . Triptans should not be used within 24 hours of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"     Eletriptan",
"    </a>",
"    is primarily metabolized by cytochrome P-450 enzyme CYP3A4. Therefore, eletriptan should not be used within at least 72 hours of treatment with other drugs that are potent CYP3A4 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    , troleandomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Concerns have been raised about the development of a serotonin syndrome in patients who use triptans in combination with a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin-norepinephrine reuptake inhibitor (SNRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the added risk of serotonin syndrome posed by the combined use of a triptan with an SSRI or SNRI appears to be very low to nonexistent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Thus, many headache experts suggest that triptans in combination with SSRIs or SNRIs can be used in most cases where both are needed as long as the risks and benefits are discussed, and patients are monitored for symptoms of serotonin syndrome. The combination should be discontinued if such symptoms arise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ERGOTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    preparations, alone and in combination with caffeine and other analgesics, have been used for the abortive treatment of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/59\">",
"     59",
"    </a>",
"    ]. Both ergotamine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (DHE 45) bind to 5HT",
"    <span class=\"nowrap\">",
"     1b/d",
"    </span>",
"    receptors, just as triptans do.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ergotamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear if it is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    itself or the other ingredients in the combination drugs that provide the most effect. There are two observations that question the efficacy of ergotamine alone: oral and rectal ergotamine have a very poor bioavailability (2 and 5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/60\">",
"     60",
"    </a>",
"    ], and controlled trials of oral ergotamine alone have failed to show efficacy in the relief of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     Ergotamine",
"    </a>",
"    tartrate may be associated with significant side effects, and may worsen the nausea and vomiting associated with migraine. In addition, vascular occlusion and rebound headaches have been reported with oral doses exceeding 6 tablets per 24 hours or 10 tablets per week. Years of use also may be associated with valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, ergotamine may worsen the nausea and vomiting associated with migraine.",
"   </p>",
"   <p>",
"    Ergots should be avoided in patients with coronary artery disease because they cause sustained coronary artery constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/38\">",
"     38",
"    </a>",
"    ], peripheral vascular disease, hypertension, and hepatic or renal disease. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    overuse has been associated with an increased risk of cerebrovascular, cardiovascular, and peripheral ischemic complications, particularly among those using cardiovascular drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/52\">",
"     52",
"    </a>",
"    ]. They also should not be used in patients who have migraine with prolonged aura because they may reduce cerebral blood flow.",
"   </p>",
"   <p>",
"    A European consensus panel reviewed the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    for the acute treatment of migraine and concluded that ergotamine is the drug of choice in relatively few patients with migraine because of issues of efficacy and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/64\">",
"     64",
"    </a>",
"    ]. Suitable candidates may be those with prolonged duration of attacks (eg, greater than 48 hours) and possibly frequent headache recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dihydroergotamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     Dihydroergotamine",
"    </a>",
"    (DHE 45) is an alpha-adrenergic blocker that is a weaker arterial vasoconstrictor and more potent venoconstrictor than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    tartrate. It is also a potent 5-HT",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptor agonist. DHE 45 has fewer side effects than ergotamine; it does not cause the development of physical dependence or rebound headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/65\">",
"     65",
"    </a>",
"    ]. It is available for intravenous, intramuscular, subcutaneous, and intranasal use. DHE 45 is often used in combination with an antiemetic drug, and this is always the case when it is given by intravenous administration.",
"   </p>",
"   <p>",
"    The use of intravenous DHE for the treatment of chronic intractable migraine headache or status migrainosus (a debilitating migraine attack lasting for &gt;72 hours) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=see_link&amp;anchor=H11#H11\">",
"     \"Medication overuse headache: Treatment and prognosis\", section on 'Dihydroergotamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parenteral DHE 45 administered with an antiemetic appears to be effective for acute migraine. This conclusion is supported by the findings of a systematic review that analyzed 11 randomized controlled trials of IV or IM DHE 45 therapy for acute migraine in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/66\">",
"     66",
"    </a>",
"    ]. The quality of the included studies was variable, and most had relatively small sample sizes. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two studies, DHE 45 alone (without an antiemetic) was less effective on most outcome measures than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/67,68\">",
"       67,68",
"      </a>",
"      ], and in one study was less effective on some (but not all) outcome measures than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In eight studies, the combination of parenteral DHE 45 with an antiemetic (most commonly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) was as effective as or more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      in relieving migraine headache and preventing relapses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether DHE contributed additional benefit when used with an antiemetic in these studies is uncertain, since the antiemetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    is known to be effective for migraine when used alone (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Metoclopramide'",
"    </a>",
"    below). However, in several studies DHE combined with an antiemetic was superior to other agents combined with the same antiemetic, suggesting that DHE 45 does have independent efficacy for migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Self-administered intranasal DHE 45 has been found, in placebo-controlled trials, to be efficacious for the treatment of migraine symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/70\">",
"     70",
"    </a>",
"    ]. In one study, for example, 27 percent of patients who administered 2 mg of intranasal DHE 45 had resolution of their headache within 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/71\">",
"     71",
"    </a>",
"    ]. By four hours after treatment, 70 percent of the headaches were resolved and returned within 24 hours in only 14 percent. No serious adverse effects of treatment were observed.",
"   </p>",
"   <p>",
"    Subcutaneous DHE 45 may be slightly more effective than the intranasal preparation, but it has the disadvantage that it does not come in a preloaded syringe. Nevertheless, patients can be taught to self inject this agent. One study randomly assigned 295 patients with acute migraine (with or without aura) to receive 1 mg of subcutaneous DHE 45 or 6 mg of subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    succinate; a second injection of the same drug was used in two hours if patients did not experience initial relief [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/67\">",
"     67",
"    </a>",
"    ]. Headache relief occurred in 86 and 83 percent by four hours, respectively, a difference that was not statistically significant. However, DHE 45 was more likely to produce relief by 24 hours (90 versus 77 percent) and was associated with a lower incidence of recurrence in the 24 hours after therapy (18 versus 45 percent).",
"   </p>",
"   <p>",
"    Similar to the triptans, DHE 45 is contraindicated in patients with hypertension or ischemic heart disease, in combination with MAO inhibitors, and in the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIEMETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and IV or intramuscular (IM)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , can be used as monotherapy for acute migraine headache. Of the three agents, metoclopramide may be better studied, but the effectiveness of all three agents for migraine has been demonstrated in randomized placebo-controlled trials as will be discussed below. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (12.5 to 20 mg every hour for two hours) is sometimes given with these drugs to prevent akathisia and acute dystonic reactions.",
"   </p>",
"   <p>",
"    In contrast to intravenous or intramuscular preparations, oral antiemetics should not be considered as monotherapy in acute migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    has the benefit over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    of a prokinetic effect on gastric emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chlorpromazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    appears to be as effective or more effective than IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and more effective than placebo in the acute treatment of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one of the larger clinical trials that assessed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    treatment in the emergency department randomly assigned 128 patients with migraine to chlorpromazine 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV or placebo. Chlorpromazine treatment was associated with significant improvement in pain, nausea, photophobia, phonophobia, and need for rescue medication at 60 minutes compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/73\">",
"     73",
"    </a>",
"    ]. Benefit extended to both migraine with aura and migraine without aura. The number needed to treat (NNT) to enable one patient to achieve significant improvement at 60 minutes was two. In addition, chlorpromazine-treated patients had a significantly reduced rate of headache recurrence at 24 hours. Drowsiness and postural hypotension were seen more frequently with chlorpromazine treatment than with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prochlorperazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are similarly limited, IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    appears to be as effective or more effective than IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    , and more effective than placebo in the acute treatment of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical trial randomly assigned 70 patients in the emergency department with migraine to treatment with IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      (10 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg), or saline solution (placebo IV) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/76\">",
"       76",
"      </a>",
"      ]. At 30 minutes, clinical success (defined as patient satisfaction and either a decrease of 50 percent or more in the pain score or an absolute pain score of &le;2.5 cm along a 10 cm visual analog scale) occurred more commonly with prochlorperazine than with metoclopramide or placebo (82 versus 46 versus 29 percent). The difference between prochlorperazine and placebo was significant, whereas the difference between metoclopramide and placebo was not.",
"     </li>",
"     <li>",
"      In a double-blind randomized controlled trial that evaluated the emergency department treatment of migraine in 66 patients, the combination of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      (10 mg) and IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (12.5 mg) was significantly more effective than subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      (6 mg) for the reduction of pain intensity at 80 minutes or time of discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/77\">",
"       77",
"      </a>",
"      ]. Diphenhydramine was used with prochlorperazine to prevent akathisia and dystonic reactions. However, the possibility of migraine benefit from diphenhydramine cannot be completely discounted. A high drop-out rate upon attempted telephone contact at 72 hours precluded meaningful assessment of headache recurrence, although none of the enrolled patients returned to the emergency department with complaint of headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    for acute migraine treatment was demonstrated in a meta-analysis published in 2004 that reviewed 13 clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/74\">",
"     74",
"    </a>",
"    ]. Study methods varied considerably, and the quality of the included studies was generally poor. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In pooled data from three studies,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      was more likely to provide headache pain reduction than placebo (odds ratio (OR) 2.84; 95% CI 1.05-7.68).",
"     </li>",
"     <li>",
"      The number needed to treat (NNT) to enable one patient to achieve significant reduction in pain with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      was four.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      was less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      in relieving pain and nausea, although differences were not always statistically significant.",
"     </li>",
"     <li>",
"      One trial found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      treatment was not statistically different than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      for rates of complete resolution of migraine or significant reduction in pain or nausea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reviewers concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    should be considered a primary agent for acute migraine treatment in emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, parenteral metoclopramide may be effective when combined with other treatments. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Use in adjunctive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a subsequent randomized controlled trial that evaluated emergency department treatment of migraine in 78 patients, aggressive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (20 mg IV every 30 minutes up to four times) treatment provided similar relief of headache pain as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    (6 mg SC dosed once) treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/78\">",
"     78",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     Diphenhydramine",
"    </a>",
"    (25 mg IV every hour up to two times) was used with metoclopramide to prevent akathisia and dystonic reactions, and no such side effects occurred in this study. However, the possibility of migraine benefit from diphenhydramine cannot be completely discounted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use in adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiemetics are commonly also used as adjunctive therapy to treat migraine. As an example, NSAIDs can be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    to decrease nausea and vomiting. The efficacy of this approach was illustrated in a study that compared lysine acetylsalicylate (equivalent to 900 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) plus 10 mg of metoclopramide with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    (100 mg) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/79\">",
"     79",
"    </a>",
"    ]. Headache intensity decreased in 57, 53, and 24 percent of patients, respectively. Thus, in patients who will not use suppositories, or who are having difficulty tolerating oral analgesics, an analgesic plus metoclopramide is a reasonable, relatively low-cost alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of patients with intractable migraine headaches do not respond to routine abortive treatments and may require additional analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/59\">",
"     59",
"    </a>",
"    ]. Benzodiazepines, opioids, and barbiturates are all options, but they should not be used on a chronic basis since they are habit-forming and can contribute to the development of rebound and chronic daily headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/4,80\">",
"     4,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overuse of opioid medications for acute headache in hospital emergency departments appears to be widespread in the United States and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], despite available practice guidelines that recommend nonopioid medications as first-line therapy for severe migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients treated with opioids as first-line therapy are significantly more likely to return to the emergency department with a headache within seven days of the original visit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sumatriptan combined with naproxen sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proprietary formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    succinate 85 mg plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    sodium 500 mg in a single tablet (Treximet) appears to be more effective than either agent as monotherapy for the treatment of acute migraine headache, as shown in two randomized controlled trials of similar design involving a total of nearly 3000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/83\">",
"     83",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two hours after dosing, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      was more effective than placebo or sumatriptan alone for headache relief (defined as reduction of pain from moderate or severe intensity to mild intensity or no pain without use of rescue medication)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       Sumatriptan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      was more effective than sumatriptan monotherapy and naproxen monotherapy for sustained pain-free response (defined as initially moderate or severe pain reduced to no pain from 2 through 24 hours after dosing without use of rescue medication)",
"     </li>",
"     <li>",
"      The combined agent was well tolerated; dizziness, somnolence, paresthesia, and nausea were the most common side effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two placebo-controlled randomized trials with more than 1000 patients that tested early treatment (within one hour of migraine onset when the pain was mild), a pain-free response at two hours was significantly more frequent in patients assigned to the combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41527?source=see_link\">",
"     sumatriptan-naproxen",
"    </a>",
"    <span class=\"nowrap\">",
"     85/500",
"    </span>",
"    mg (approximately 50 percent, versus approximately 16 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/84\">",
"     84",
"    </a>",
"    ]. Even at 30 minutes, there was a statistically significant pain-free response with combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Due to the pharmacokinetic properties of the proprietary formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , it is not certain that taking sumatriptan and naproxen together as separate tablets would have the same additional benefit for acute migraine as the combination contained in the single tablet formulation, and this question was not addressed in these trials. The proprietary formulation is designed for rapid disintegration and release of sumatriptan succinate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/83\">",
"     83",
"    </a>",
"    ], and naproxen in sumatriptan plus naproxen takes a longer time to reach maximum concentration (approximately four hours later) and has a lower maximum plasma concentration (about 36 percent less) compared with standard naproxen sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Abortive therapy plus parenteral dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;When added to standard acute migraine therapy, parenteral treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    reduces the rate of early headache recurrence. Supporting evidence comes from a meta-analysis of seven randomized trials conducted in emergency departments or headache clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/86\">",
"     86",
"    </a>",
"    ]. All patients (n = 738) received standard abortive migraine headache treatment, and were also randomly assigned to treatment with either a single dose of dexamethasone (intravenous or intramuscular, 10 to 25 mg) or placebo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the pooled results,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      was significantly more effective than placebo for reducing migraine recurrence from 24 to 72 hours after treatment (relative risk 0.74, 95% CI 0.6-0.9). The number needed to treat to prevent one recurrent headache was nine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      provided no additional benefit for immediate relief of headache.",
"     </li>",
"     <li>",
"      There were no significant differences regarding adverse events between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and placebo groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were reported in a second meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/87\">",
"     87",
"    </a>",
"    ]. Adjunctive treatment of acute migraine with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was not beneficial for prevention of recurrent headache in a small trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we suggest adjunctive treatment with a single dose of parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (10 to 25 mg) to reduce the risk of early headache recurrence for patients who are treated with standard abortive therapy for migraine headache in the emergency department or clinic. However, frequent use of adjunctive dexamethasone for headache increases the risk of glucocorticoid toxicity and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H134381582\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of novel drugs are under investigation for the treatment of migraine, including calcitonin-gene related peptide receptor antagonists and serotonin 1F receptor agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CGRP receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic modulation of calcitonin-gene related peptide (CGRP) activity offers the promise of future treatment options for acute migraine attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of randomized trials suggested that the investigational CGRP receptor antagonists telcagepant (MK-0974) and olcegepant (BIBN 4096 BS) were beneficial for acute migraine attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. However, development of telcagepant was stopped due to concerns regarding hepatotoxicity, and development of olcegepant was halted because of poor oral bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/93\">",
"     93",
"    </a>",
"    ]. It remains unclear whether other orally bioavailable CGRP receptor antagonists still in development will be hampered by liver toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76765403\">",
"    <span class=\"h2\">",
"     Lasmiditan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasmiditan, a selective serotonin 1F receptor agonist that lacks vasoconstrictor activity, was effective for treating migraine in a preliminary randomized placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/94\">",
"     94",
"    </a>",
"    ]. However, lasmiditan had a relatively high rate of serious adverse events, particularly at higher doses; the most common were dizziness, fatigue, vertigo, paresthesia, and somnolence. Further study is needed to determine whether lasmiditan is tolerable at effective doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DRUG CHOICE AND SEQUENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies have been considered for the sequence of acute migraine therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step care within attacks &mdash; Individuals with migraine are initially treated with the safest, least expensive medications and progress to more expensive migraine-specific medications after a couple of hours if initial treatment fails.",
"     </li>",
"     <li>",
"      Step care across attacks &mdash; Patients are treated with the safest, least expensive medications during the first migraine attacks and progress to more expensive medications for subsequent attacks if the initial attacks are unsuccessfully treated.",
"     </li>",
"     <li>",
"      Stratified care &mdash; Treatment is assigned based upon the severity of migraine-related disability, with safe, less expensive medications administered for patients with little or infrequent disability and more expensive medications for patients with moderate to severe disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized, controlled trial of 835 adults with migraine compared these strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/95\">",
"     95",
"    </a>",
"    ]. The step care within attacks group received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (800 to 1000 mg) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (20 mg) as initial therapy for all attacks; patients not responding to treatment after two hours in each attack escalated treatment to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    (2.5 mg). The step care across attacks group received initial treatment with aspirin (800 to 1000 mg) plus metoclopramide (10 mg); patients not responding in at least two of the first three attacks switched to zolmitriptan (2.5 mg) for the next three attacks. In the stratified care group, patients with mild headaches (based upon the Migraine Disability Assessment Scale [MIDAS] grade II) were treated with aspirin plus metoclopramide, while those with MIDAS grade III and IV were treated with zolmitriptan. The latter two groups had significantly better outcomes than the first group as measured by headache response and disability time, although patients in the stratified group had the greatest number of adverse events.",
"   </p>",
"   <p>",
"    These findings are consistent with recommendations from the headache consortium that rejected the step care within attack strategy and promoted the idea that migraine-specific therapy be used for moderate to severe migraine, once the physician has established that first-line medications are not effective for a particular individual [",
"    <a class=\"abstract\" href=\"UTD.htm?20/44/21194/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"       \"Patient information: Migraine headaches in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For abortive therapy, we recommend either the step care across attack strategy or the stratified care strategy described above. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Drug choice and sequence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We typically begin specific migraine therapy with a triptan for outpatients with moderate to severe migraine. There are no efficacy data that definitively support use of one triptan versus another; different pharmacologic properties and delivery routes may help guide the choice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Choice of triptan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial treatment of patients who present to the hospital emergency department with severe migraine, particularly if the migraine is accompanied by severe nausea or vomiting, we suggest treatment with intravenous (IV)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      (10 mg). When giving IV metoclopramide or prochlorperazine for migraine, we suggest adjunct use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (12.5 to 20 mg IV every hour up to two doses) to prevent akathisia and other dystonic reactions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antiemetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A more aggressive alternative option, based upon the results of one clinical trial, is high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (20 mg IV every 30 minutes up to four doses) given with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Metoclopramide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      (DHE 45) 1 mg combined with IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      10 mg is also a reasonable alternative for treatment of intractable severe migraine in the emergency department, and it can be used if metoclopramide monotherapy is ineffective. Parenteral DHE 45 should not be used as monotherapy. DHE 45 is contraindicated in patients with ischemic vascular disease involving cardiac, cerebrovascular, or peripheral circulations. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dihydroergotamine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are treated in the emergency department or clinic for migraine headache with one of the standard abortive therapies discussed above, we suggest adjunctive treatment with IV or intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (10 to 25 mg) to reduce the risk of early headache recurrence. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Abortive therapy plus parenteral dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sublingual, oral, or rectal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      is the drug of choice in relatively few patients with migraine because of issues of efficacy and side effects. Suitable candidates may be those with prolonged duration of attacks (eg, greater than 48 hours) and possibly frequent headache recurrence. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ergotamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abortive treatments are usually more effective if they are given early in the course of the headache; a large single dose tends to work better than repetitive small doses. Triptan treatment, in particular, should be given at the first sign of pain in patients susceptible to cutaneous allodynia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors predicting response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many oral agents are ineffective in migraine because of poor absorption secondary to migraine-induced gastric stasis. In particular, a non-oral route of administration should be selected for patients whose migraines present early with significant nausea or vomiting.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and many other analgesics are not advisable in the patient who requires frequent medication since they have been associated with rebound headaches. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic headache treatment is indicated if the headaches are frequent, long lasting, or account for a significant amount of total disability. This topic is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"       \"Preventive treatment of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/1\">",
"      Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/2\">",
"      Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000; 54:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/3\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/4\">",
"      Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/5\">",
"      Col&aacute;s R, Mu&ntilde;oz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/6\">",
"      Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010; :CD008041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/7\">",
"      Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000; 20:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/8\">",
"      Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/9\">",
"      Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/10\">",
"      Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010; :CD008039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/11\">",
"      Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 1989; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/12\">",
"      Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 1985; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/13\">",
"      Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2012; 2:CD008783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/14\">",
"      V&eacute;csei L, Gallacchi G, S&aacute;gi I, et al. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study. Cephalalgia 2007; 27:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/15\">",
"      Myllyl&auml; VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/16\">",
"      Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010; :CD008040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/17\">",
"      Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/18\">",
"      Lipton RB, Stewart WF, Ryan RE Jr, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/19\">",
"      Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/20\">",
"      Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004; 56:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/21\">",
"      The Subcutaneous Sumatriptan International Study group. Treatment of migraine attack with sumatriptan. In: sumatriptan. From molecule to man. An official session at the 8th migraine trust international symposium. London, UK, 28 September 1990. Proc Eur Neurol 1991; 31:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/22\">",
"      Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000; 75:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/23\">",
"      Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev 2001; :CD003224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/24\">",
"      Eletriptan (relpax) for migraine. Med Lett Drugs Ther 2003; 45:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/25\">",
"      Havanka H, Dahl&ouml;f C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000; 22:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/26\">",
"      Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997; 49:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/27\">",
"      Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/28\">",
"      Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 2003; 78:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/29\">",
"      Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database Syst Rev 2001; :CD003221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/30\">",
"      Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998; 38:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/31\">",
"      Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2:CD009665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/32\">",
"      Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2:CD008615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/33\">",
"      Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2:CD009663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/34\">",
"      Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/35\">",
"      Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991; 325:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/36\">",
"      Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/37\">",
"      Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH. Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 1997; 54:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/38\">",
"      MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/39\">",
"      Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997; 49:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/40\">",
"      Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 1997; 49:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/41\">",
"      Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/42\">",
"      Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmacia Axert marketing will claim \"fewer side effects\" for triptan. The Pink Sheet 2001; p.7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/44\">",
"      Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/45\">",
"      Klapper J, Lucas C, R&oslash;sj&oslash; &Oslash;, et al. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/46\">",
"      Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/47\">",
"      Christoph-Diener H, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004; 63:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/48\">",
"      Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/49\">",
"      Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123 ( Pt 8):1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/50\">",
"      Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 Suppl 1:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/51\">",
"      Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/52\">",
"      Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006; 67:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/53\">",
"      Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/54\">",
"      Liston H, Bennett L, Usher B Jr, Nappi J. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med 1999; 159:511.",
"     </a>",
"    </li>",
"    <li>",
"     5-hydroxytryptamine receptor agonists (triptans) - Serotonin syndrome. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150367.htm (Accessed on November 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/56\">",
"      Evans RW. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome? Headache 2008; 48:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/57\">",
"      Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother 2008; 42:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/58\">",
"      Rolan PE. Drug interactions with triptans : which are clinically significant? CNS Drugs 2012; 26:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/59\">",
"      Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 1996; 71:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/60\">",
"      Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/61\">",
"      Dahl&ouml;f C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/62\">",
"      Waters WE. Controlled clinical trial of ergotamine tartrate. Br Med J 1970; 2:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/63\">",
"      Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/64\">",
"      Tfelt-Hansen P, Saxena PR, Dahl&ouml;f C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123 ( Pt 1):9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/65\">",
"      Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/66\">",
"      Colman I, Brown MD, Innes GD, et al. Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med 2005; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/67\">",
"      Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/68\">",
"      Gonz&aacute;lez-Espinosa LE, G&oacute;mez-Viera N, Olivera-Leal I, Reyes-Lorente R. [Treatment of acute attack of migraine with sumatriptan]. Rev Neurol 1997; 25:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/69\">",
"      Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990; 19:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/70\">",
"      Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/71\">",
"      Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996; 53:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/72\">",
"      Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995; 2:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/73\">",
"      Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/74\">",
"      Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004; 329:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/75\">",
"      Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med 1996; 14:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/76\">",
"      Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/77\">",
"      Kostic MA, Gutierrez FJ, Rieg TS, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 2010; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/78\">",
"      Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/79\">",
"      Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/80\">",
"      Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 1997; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/81\">",
"      Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002; 39:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/82\">",
"      Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004; 62:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/83\">",
"      Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007; 297:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/84\">",
"      Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 2008; 71:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/85\">",
"      Haberer LJ, Walls CM, Lener SE, et al. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2010; 50:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/86\">",
"      Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/87\">",
"      Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. Acad Emerg Med 2008; 15:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/88\">",
"      Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. Emerg Med J 2008; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/89\">",
"      Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/90\">",
"      Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/91\">",
"      Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/92\">",
"      Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009; 73:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/93\">",
"      Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/94\">",
"      F&auml;rkkil&auml; M, Diener HC, G&eacute;raud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/44/21194/abstract/95\">",
"      Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284:2599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3347 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21194=[""].join("\n");
var outline_f20_44_21194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MILD ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRIPTANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Preparations and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of triptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factors predicting response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations to use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ERGOTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ergotamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dihydroergotamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIEMETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chlorpromazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prochlorperazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use in adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sumatriptan combined with naproxen sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Abortive therapy plus parenteral dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H134381582\">",
"      INVESTIGATIONAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CGRP receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76765403\">",
"      Lasmiditan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DRUG CHOICE AND SEQUENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3347\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3347|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?18/16/18688\" title=\"form 1\">",
"      Headache diary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=related_link\">",
"      Patient information: Migraine headaches in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_44_21195="Sleep study indications";
var content_f20_44_21195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for a nighttime sleep study in patients with neuromuscular and chest wall disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Symptoms of sleep disordered breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Excessive daytime sleepiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disrupted nocturnal sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Morning headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Changes in personality, concentration, or memory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Snoring (with obstructive sleep apnea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Awakening with shortness of breath or choking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial blood gases showing hypoventilation (PaCO",
"        <sub>",
"         2",
"        </sub>",
"        &gt;45 mmHg [6 kPa])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FVC &lt;50 percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severely reduced PImax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained cor pulmonale",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PaCO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of carbon dioxide; FVC: forced vital capacity; PImax: maximal inspiratory pressure at the mouth.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21195=[""].join("\n");
var outline_f20_44_21195=null;
var title_f20_44_21196="Distinguishing TRALI and TACO";
var content_f20_44_21196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helpful features in distinguishing TRALI and TACO",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        TRALI",
"       </td>",
"       <td class=\"subtitle1\">",
"        TACO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body temperature",
"       </td>",
"       <td>",
"        Fever may be present",
"       </td>",
"       <td>",
"        Unchanged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure",
"       </td>",
"       <td>",
"        Hypotension may be present",
"       </td>",
"       <td>",
"        Hypertension may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory symptoms",
"       </td>",
"       <td>",
"        Acute dyspnea",
"       </td>",
"       <td>",
"        Acute dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck veins",
"       </td>",
"       <td>",
"        Unchanged",
"       </td>",
"       <td>",
"        May be distended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auscultation",
"       </td>",
"       <td>",
"        Rales",
"       </td>",
"       <td>",
"        Rales and S3 may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph",
"       </td>",
"       <td>",
"        Diffuse bilateral infiltrates",
"       </td>",
"       <td>",
"        Diffuse bilateral infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ejection fraction",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAOP",
"       </td>",
"       <td>",
"        Most often 18 mmHg or less",
"       </td>",
"       <td>",
"        Greater than 18 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema fluid",
"       </td>",
"       <td>",
"        Exudate",
"       </td>",
"       <td>",
"        Transudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid balance",
"       </td>",
"       <td>",
"        Neutral or negative",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to diuretics",
"       </td>",
"       <td>",
"        Inconsistent",
"       </td>",
"       <td>",
"        Significant improvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White cell count",
"       </td>",
"       <td>",
"        Transient leukopenia may be present",
"       </td>",
"       <td>",
"        Unchanged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BNP",
"       </td>",
"       <td>",
"        &lt;250 pg/mL",
"       </td>",
"       <td>",
"        &gt;1200 pg/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TRALI: transfusion-related acute lung injury; TACO: transfusion-associated circulatory overload; PAOP: pulmonary artery occlusion pressure; BNP: brain natriuretic peptide.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14:682. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21196=[""].join("\n");
var outline_f20_44_21196=null;
var title_f20_44_21197="Distribution of skin lesions";
var content_f20_44_21197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of common skin dermatoses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Flexural distribution",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acanthosis nigricans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atopic dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bullous pemphigoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Extensor distribution",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoriasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atopic dermatitis (infants)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatitis herpetiformis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Xanthomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Feet/hands",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eczema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinea infections and \"id\" reactions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Wrists/ankles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen planus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scabies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Contact dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eczema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Photodistributed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Photodrug eruption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pellagra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porphyria cutanea tarda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polymorphous light eruption",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mouth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucous cysts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukoplakia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fordyce spots",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyogenic granuloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Skin cancers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Axillae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acanthosis nigricans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hidradenitis suppurativa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Impetigo",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hailey-Hailey disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Achrocordon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Folliculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythrasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Contact dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Buttocks/anal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Folliculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoriasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hidradenitis suppurativa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen sclerosus et atrophicus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptococcal cellulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kawasaki disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Scalp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seborrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Contact dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinea capitis and kerion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Discoid lupus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoriasis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21197=[""].join("\n");
var outline_f20_44_21197=null;
var title_f20_44_21198="Structure of adhesion proteins";
var content_f20_44_21198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Structure of immunoglobulin family of adhesion proteins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 318px; background-image: url(data:image/gif;base64,R0lGODlhEwI+AdUAAP///wAz//8AAAAAAABmMz9m/4CAgPDz//8/PzBZ/8DN/+Dm/2CA///w8MDZzYCZ/xBA/0Bm//8wMHCN/7DA/9DZ///AwP/g4P9gYFBz/8DAwP+AgP8QEP9AQJCm/yBN//9wcP+wsP/Q0P9QUEBAQP+QkKCz//8gIODg4DAwMAAZDPDw8BAQENDQ0KCgoCAgIP+goJCQkHBwcGBgYLCwsFBQUAA/zL8ZDGB5bO/18i9mzL9JPAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAATAj4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU0ygxBi4rRy0kLgAkMlcrM+HV5+hjLgPsAyRHGgMGAO5XMwMy3+n7/FgoAyw0AGgxb4UBEjVoAIg3rx6RFuVquEBhQCBFgdkIanghD4WGGiRIxBCCQgZChSjKzWjRr2W/GPiKpGBhIMWAFgzpvRvyL4WB/xk1cuYEyM4FC3cEZxwcoI0FzXIoWPh06rIqOgPyHrr7KW/oTiEtBryQEWOF0KwDUgwhMUDIihg1bBqAqe/aAKVsBVrdG23dV49bDVT0WoQGiaMpzjb8ylbIzBgwBQ/QCwCrUsEo+Gp+xpGEAZAAnLrQEGM02q8LZ9DQ4DQsTbaL17al90KDDHlhE7uokXu1DJabgytDUYPdi5EtiotdfZoICptpWd5+cS+2kMYA1rnLSgP6vO7sUmQWTr68+fPo06tfz769+/fw44NqEGJDBwkC8uvPL6HDhhANhEGfffjtp19//wUIxoD3GXigfwAKWF+DDgqAYIQSElihhRAqKP/fLg2U0MGGJArQQQkeYhHiiCVWeGKKV6zYoosobiHjjAa+yMWNOOqn44e2iIBBjyViIMIVQhJJopFIDqlkhUxakeSTDkYppZNU7mclkK9cMEKFJ2DwnwVkllkfBidAecEUXoIpZghlmrkBmmqy+aWDYY4ZpwVnplnlmlK0ieebe/I5p58GYgBooHcamCece/ZZJ5etlMCBgSPAsOgSF8DQaH4clBCFpZhq6kSnnwoQ6qiX7pfppkqgauCqUJDqqqlNyLofrbW2qt+rp3o6q6iUyqGBYMgmKxhlZzTAIqgbwPrEBRv4aiKMSDi7a7RUUGttB9geoa1+HHDLZrX7gdv/xLjQSnsquj6GK+6zqpobKLz5qVvsG1i1428786BxQYH5gSAvFA2AsJ8E7hIx8H4Gq6jwgQ0P8bB+Ecc4MX8VC3FxwQc/kfDCHXtMsAAZWzEyxfu60e+//gZsRgOISnDkFiIQfMLBNB94sxY567dzEj3z93MWQec3dLY1H41F0gIszbTPXEAtdctpvAwzOzKT0QDBI4RMRQONShDu17+KPQXZB54NttpSsM2f22l7IbeF8qKdX9h2lw031l1ovXXXY2yMgRhYgnCE4YhjvLh+h4eR+OP5RQ7G5JQLYPkXmAN+huAwEx6GBQeSQbAFRZDOn+n6oU6E6haynp/rQ8Au/4HsAtBee+ljnO7551vHbAaLHJScxQWtdlAE8cZjgXy+y4Pa/BXPmxi9qtNbUb3y1xdPxva/mwH6v6J/IYJ+G5ixgX4/n59f+mWsn1/76KvP/hDuCwA/GfILcHT++xtD/5wWvi+MT3hkmBgH/qaiVilOCApkYIwcOIQIzoyCEASVBFWGwQyqaoNVaEAHCwiGAwKsDAXaHBmcdDshpBANLBzCC88QQxdWDoark+ENaZhDEpYweCckg35CgIYQ6GcIQyziEYWQxDMYMT9IzA8RnbhEJkpRiVD04Q+BmBUhzg4NsIti7sBYxdaRMYsAMOMZwihG3ZGBjVr0ggm5VgY1mv8BjnYsAx6/uMYy8vGOVUzjH/UYyDhuYY5dHEMe3+jHMfYRjYscwx4dCUg0CpKShLSkIbWAyPJ5oYlmeKIAxDjFUDaylGUQJSmxOMpVUlGTm8RCJ1G4QzPUEAAztGUPc1mGW/JyhT3EZS17GcxYypKLiRSDBcsgwoJVUIMXdKYHFxhNlD3zg9V84DRBOLYRGvMKsyQDAO03P/zVL373E8I40VlOdZ6Tf+l05/vI6b9vchKZnvQC876XvO5lrwrgI8I+xxDQIQxUDAU1qPT4CT17ZiGcjCzmF3z3Ot6JgaK7k6gXMCoE2+HOjQDwaO8i6dApQDSBkGucNIvAOMk5zgj/Lb3cS1maUpeulKbD9ELnSmqFk45BbwLgWxfuZjZxva1vbTNq3YbqN6XujZtLIGrejsrUpPIUnPhEQ9EsREApEayoUzNa1b7Ks6aN1ariMivOyKqErdrsrHO76jG5mE8wfAxlUCXCyuIaq5OlLIQbwxun/JrXIexVsH2FWGGFcFiwJhZjiwVAYyMrV58yk17l+qfD8HWtdWHWXlHwVrrgxq56adZinNVXVD97Wo+l9m+lzWy3XivXh2Z1Dbb6Fa6YoCtyEesJud3bbjklrF391gnBDepwY1Vc37KqVNPrLaiOi1xrKTe6zZ1ube9J1zZcAEv7eVShJPUnNoFXaISK/9ShJhXa8yotvXEib6Ja+1036Sm+6y2vee0LKfzSSb/bnSsQ61qGKWUJcl2FgoEPrLkEP2HBB97SFCCcJQlP2L1UsnCAq2DZNfCISD/Kwod7FGIViYhKJY7RiZ+UYhXTi8Q1aoNHNEDjIdBAMMABgEdyvGO31PgIZhlPOjrcBgadbGEjSFCGKOQgCSQZQ18w8oacrOQFTejIB3oyZYl25SlrOQ5aA8AKoMMOvUBnG5UBiBDuMZsifCSZwyCAnOdM5zrb+c54zrOe9zznHSDgz4AOtKAHTehCG/rQiE60ohfN6EY7+tGQjrSkJx1oL8RjJ/eYwQrewpJ/FEUI/dJGO/+OEMRi8PnUqE51qm/A4Fa7+tWwjrWsZ03rWsMSC5cWwlHQPITbrEMtaX5BCmLAkTYXASsE5oWql81sZrPa1tCOtrSnTe1qU8nSDmGHEV7wAgBwJDNYgQkLYNKWl+kF2cdotrrXnednW/vd8I63vOc9I2zvhCN62TQNAHKYmGBFAzZZgbZnrAE0o9sY7E64wt1N74Y7/OEQf3UX7JKY7ABEBjKoTXEEcxsWpFkDKGCJto2ggUwzSxgKT7m6GR7xlrv85S4PnL+EQGx28CYtQ7DJjSczhJEX4V/GcIDQh070ohMdBypIutKXrgIcGP3pUI/603Ow4arfgchWz3oksK7/9a4zguteD/shwC72sguC7GZPex/Qrva244Htbo/7HOAu97q77LZ2z/vV8a73vsuB7n4PfBgAL/jCc4Hwhk88Vrur+MaTAfFLxjJ/OhT5KVPe8fyA/FBXrKQWh5DzII4x5quheaBh+EkaVvDplZT60TOj9NRL1XvvK6f/ztdO/B1vfm/vemjAvgrJBVausqsq6jIh+MtNgnSL3/tn/D5urJ3tt0gb/XNNv/mv53sZ7vrXsQWWYYNVrMRIhn1lPF9kagWazspKtbUKbcvld8X510XVHTXVCEAVqv3RGv9hzJ8JMcU5M0UEAahTA9h/wfB/SiBSF7VIDBgGHIWAv6CA/0lwUGGQUABggXbVTxKYgNoHBusET+0EACEoQPHUgb1AgZRDTczUQcvkNd6EgrqggkbwS2PgSzl1gxolg7dAg0UASql0SqzEgyn4gV9AUqPTSCAlBnBEhLngg0SAhGAwSUuYhLfmhLQAhW10Rq10SVU4hYWEhbWghVYkAKhEBqpUhmc4Bmkohj1ohBuVgyrVQsKkOTgUO274hoxXONDUgiv1gj8Vg3kYC2RIgu9kgiNYgmIwQINoC4WYgQtFUByoUNjDUNbTiGMIh17wgGAQgZw4UVKIiazwiABQgF2wU9dkhzZlTaKYhZpoN/VnI/dXBPkHf4Y1i61IiK9oN+mHNP9sFVZcBVeIlYuyQIomI34aszBiw32RNVnE6Ip72CzVdy/XxwSxBVpQIFrx8ozQOGBsgHzYlSq8Ul3QFSziaHwTR2M/BgA3ZgA8pgHvCBxmcXJgIRj6wI1oYIxFUF+DQntkIl9aQl8YJl7qZXsB+XgzN2b+YmbsYHBqBgBsRmrtIA74CDzRuAYUlmEO5gQZiXob2QW5BpF3sWkx0GntoA+hJnA+RwTfEBbGVpFjoI/ZAnowBn8jhiOeJwYhuWtF4Gs4F2zDVmxJ8A/dBpNlIJNt1WUVQmVQZjdK2WRftgYhuZJCwG3eNgDgNgDiRm5pVmZDUBwKYZRRoHJkqWp+Rmn/aJmWasloTRCS+OYWK7BvLNBv4vBvATdw6rgNK8AW9yiWT1CWgMlnLAdzhHmFzgETFbcOLIBxGicPBtBxHxdy9PCSOmYTnmEAQuaXTBCYnIlng1mYMMcEYQYANTcANwdsAKBz/9ZzlBkPC6mZTtCZsklnnwmaMQebgjCbulmbthlxuJmbuimbvNmbD/ebgSB1UYd0TMd0ToeczvmcVGecWoSU0vk71FmdgHOd2Nky2rmdxdKd3skl4BmeHzKe5Bkf5nme75Ge6tke7Nme6/Ge8Jke8jmf51Gf9lke+JmfwrGf/LkZ/vmffBGgAmoVBFqgLnGgCNoPCrqg+9CgDnoV/7sYod8EoRRKDRZ6odKQoRrqexPaoXHEoSDaDCI6ostQoiaaDCiaosewoixaDC76ov73oTKanTRao9x5ozj6nTq6o+LZoz5ankAapOg5pES6nkZ6pO6ZpEoan0zapPT5pFB6n1I6pfpZpVtwABTwABGQAAHwpWD6pQkQAQ9AAQcQBlrKpV4apmA6pmV6pmCQpl3Kpm1KpmaKpls6p3QaAG56p3iqpnvKp3YKp14gp2tKp31KqJ4zngfgAREQqJAaABHgAYp6BY36qJG6p5NaqVZwqZmqqZSapY76qXS6qVzgqaQapqaaBaiaql+6qljTnRXAAK4KqQxQAVcwq7UaqP+3mqu0uqt02qtWoKvAyqbCOqy/WqxgeqxTQKzK+qXMSinXuQAZsKcfwABlqgDauq1bygAfsKcMsABTQK3Wiq0UsK3c+gDeCq7iKgXkSqfXmq3oqgDd+q3B2q5R8K5sGq/nOq/1yq5UoK9hyq/zSq/qaq/Giq9PILBgSrD+erAAy6MXeQYeAAFsmgEmoLBKsAAmUK1hCgEeEAUVe7EZ6wQc67FgCrIia7FhirEamwQny6YqCwUj27Il2wQx+7Ehu7Ik+7JIkLMpu7NOULNg6rIm27EyK7RAIpMHgKlfCgEP4LM4+wAs+6qcegRN+7FRG7BUq6pXawRZm7JbO65dC6b/EfC1RRC2Tzu27lq2VusEahsAUCu1TLAAbiupaDsEcTu3XFu1ePujEzsGC3CoATABeQu3ExCmCUC3QjC4YWq4WHAAidumjAsAjgumkGupkyumlXu5X5q5nbq5fFq5lku4oFsFkqu4jOu5hXu4TZC6lLu0WAq3CJsAuLoFFXCoH4C2B1C7t6sFuduwvOu7XBC8X7q7SdC7bfq7WWC8AYC8yUu8uKu7X6u8Ysq8WOC80FukgRunh5oBrisFB4CyCXC1B/C94RsF49um5ou+hUq+7Vu06QsF6yum1eu+XVC/fMqp5yu/78u+8kGKm8sAYpCsE3AEA1zAmIvAy6rAn8vA/9DqwIWLBAkcBgZsBBUMBhfMvd5YBgrQpmRwqApQBB8spiEMpiNMBCXMpyf8pSk8BCucAC0cAC8MwyA8BiKswjcsBjkMH4+IqRBAuliwACwbAUUAxEJ8BUT8qkf8tElsBUssqU0st09cBVFsxFMcxGRwxUSAxFtcxBwcPMnWvGD6AGbwAGD6uxVQxmecxkOwxl9qxmWAxl+qxmw8x278xndMBnQcALcLxwEgx3ycx+5RiJMLAfNrqSx7wEJwyIncqYs8BI5sBgcQyY38tI+MupZ8yXKbyVRQyQ8MAJNcBqA8wUjavV2wpgR8Br8qw0KgymjQykMAy6xswq8cwbXMwv+zjMtmIMsAQMu9bMuFPLtKAKYUgAYUAKZDYMzIrMxCwMxnkMxfusxfeszR7MzPXM3NPM0AAM1mIM0B4MPEnAQojAYrTM00bM7YXM5ncM7ZnM7tjM3d7MLqzM3sbAbuPMyozAX37MHrTM/xzM3zDM/4/M8E7c8CPdA1TAbu3M8MLc/sUYgOPQb5PNFiUNEAXdACbdFhkM8KXc/h/NEBHdL63MFj4M1lAM7obM3fbNAsndIuvc0kPdAvTQYqTdMyLc77vAXAXAa+/Mu87NPC3NNk8NNEPQY/DdQBsMrBrMtH7cCuXNJiXAajTAalzMiijMmUvMlVPQZXLclaTcqbnNX/nbzVodzVYvDVp2zSYgDIgjwGfWzHcdzGdazHc43HdS0Ebk3XfkwEe43XfQ0Afz3IeS3Vg2MGXiy4YNzFTvzFTMzYVOzYUgzZWqzYj03ZVRywiy0EiS0GXKzTbH3ROxwGPWzDwkzaDh3DM7zQqo3DE93aPNzPsI3aGW3YoXMGGfwFG1wEue0Fu00Evd0Fvw3WQe3bCwzBSy3BWE3cyW3Bxw3aU03J+Huq8Iu1052l1Q22160F+lu+1u2/+Zvd2g3e1A3AabvdrCreax3dlCy9wHuo3o0E1sun2Jur8D28y1u89x29+T295i3f7t28+421AZ69Ax7Gh40GrHu6nyy6//ENs6bryWnr4Ie74BJOBLBrv0tg4ZFL4XUb4R2uuHnL4Zor4rK701+wt2ybr3d7tq/rtHK74lBgt37r4kyg4pk9BDTutS+utTneuC2evjjetzy+BENOtjV+4ZpBnUT7pUaLs0irszxrs0kMtE+rtE3Q5AHw5HUb5UE75UV7s12OslcuBVrO5Rvu5WX+BGcu5mlO5nKL5QE8zjOerANrrgX7r/c6rnbesHj+sOu65+7a58f75+iq5wnL5+Uqr4cOsYI+6Iver40e6Imer4T+vIaerpQepuG6L7J66bsarVLgrM8q6lFA6spq6lCA6sWq6qsO6rXq6k3A6sAq69Cd4P9v0KquCquRO6q7yuuW6uu1CuydKuy7HqqiCuOpSuyfbOzLjuyxSuedmqeEq7gZ8KZ/qqeIeu1+muLUHqgJwO1KbuTfvqfhju3ZXu1tKu5xWu7bju7qEZyyqQMFUO/2fu/4nu/6vu/83u/+/u8AH/ACP/AEX/AGf/AIn/AKv/AFsBfy3pk28KwSP/EUX/EWf/EYn/Eav/Gu6vAPH5gRz/EiP/IkX/Imf/IoX6se//FlGfIp//IwH/MyP/Myv/Isr3IuT/M6v/M83/M+v6c2f/MKl/M/X/RGf/RIf/F78ZxGp5zLqXTNyfRSb3TRaaXnEKNW343snfUSG9pcf+Je//X/c47iYu+kZF/2UXr2aE+lar/2V9r2bt+f0h73pDf3dD8NWH/3qJD3em8KfN/3pPD3gC8Kgj/4oFD4XE9jaGYWwEEQBhCWOgaPQzCPQ6D4SCD5gYD4WV8c+rAOI8FmdJSaDSkErskS2kGPBOEQgKD5Vv9r14GVv5YZNPANnsYUpM8OMyD6PFcEbKH6f8Cehgrug5ruwg/vherubJqoxG/uw7/8iNr8xw+ozG/8p4r8igv9YXAUKPAPNQAAYNmTTPGT8YBvYrH7bub7fsCozk6qzN7sys7+0N7r7/+p7T8Fuv7s456260//8Q8EAOGQWDQCDp5IgNl0PpsRz+FYtQqT/0vo1imlXsFg2cAQG9AApIGm+HoBXgMUQENmsWpqjWHQZ9MHSMIGCQvD+PoSFckMGwkrGLgktxgqHIsgJzWbKi+JMjc1Oz2FQEMlR0kBTE8pLUlZW59SL2NlOV9Vj1oG3FiEZhiFUGgGWEhYBmQADcZo9FA0pFeE6gR1sR0RFxUNsj0XMrY+GB4oFNDTKR4YPigXLsPHy8/T0dfb3+PFocjN7e+xcweFATxH8vrRA6gA38BZBg/ye+Kvnr2G+hohnKgQ4EWCEAtpdEJxoceH34ik6LMMAIo+MwykMFCDTDNjzFaw0WOkhZkUGqihFFplG7c+3oYSegDhSQYTIK8sMP8hkQkED42WNn1KSCrVAFaxMnXiFKqVrk/AGso6duugs07SGvIgtglZrlPRXi00V2vZKm+bxB3El63fI4Cr6kXpos+caioHpCiWYohKGnWQplljRE2iP0lBAyhqNHPoIwe0VH1gOMyCtUwifAGDGu5qcK8DxB5EO7DteLh1h+GtmjUY13Rzy56d+qvvg8CVVxnevHhU6MKZQ3Ce8bpp79+TjuZWGjyABQmcTIh+6cAEJwmqn0+/3lH79/HRN1GPzX4T+MbzY2I/Xfpj4j8A5+PPPf+Kk08/+hopMIAD/wowgAFVkZDC8jjssBDxFiHvuwMcSiCXbCoI8AMIkSjxRGz/UmxiRStI9O9FXWJkYkbpXBQqxwB25NFGH1WEsEYDb1TlxyCLOHLCJGEp0sMpqSTKqG46PCDADFgk5QCJEqBPy7q69ORL/8Tcskz2wEyTzKTONNBINeFs04gxmeCyTjTvpHOoOCdcs8pBQQMRSw4XDIAB7yIR8IhEFzWt0Qsf5YRR/SplItLQJp2gCkgvdbQIUCXFdFRLSxWV0FXLMzQREUNTwD/wAlSgCFkNpLUJW4nAdUJdmeB1CF8TADYAYYed9btae1XWO2aTzXXZXVmt1jtXj+JQCwiqy2YBsSIoYttusfkWNnGrIlcXc3ND9yt1VWE3XHe5BU9eIsa1F1x8/9PV91xrAR4KW2G+q6CJBzh8oIlcDGYC4fIUZoLhgxNeeIiGA3gYvIgDOBFjjb/j+JWPK5a4FIohtjjglbEZGNakFoRA0GwOEMtTIWKemT+bh8iZw5pV9bk8oCntuSqdCeQZAKHBI/pmpkdUmuWpL3G5vPw2La/RYoXA2sOth/C6Q7C71vRractW9OxfARCbQ7Ld1hptqukmxGrwmqDAQwqaGCLvvfsW4u8O+WbCbyb0JjxwwREH3HAABuew8AAYDyBxyRevW/Mr7v6O2g59PfxYD0OvHFnwSoc8WNIz/5zD0l0vD/bVQc9889uL6Ny72FFfnPfvUv/du+Bpf7314v9lD1x402YfvfbHcY9+CN1NWz5W35HvHXrrQSPeeeOhV/375B/nPqnmTwfedulvpz60yMubXPTL48fecscpr5x+8OSfH3/9/ye+/X2nf+yLnvtAEzfwkK1tZhsb2hT4HQZGMFRcS1vWFigtCqaKaxvk1NwMuDkEwuxoP5Ma1LzjNKN9BWkZOmEJhya1pcGwaUpDoWlUOEMWmlBVIRThlV5VHpKlzGQnc1jJOnYxlG1MZatYYsia6MQjEjGJUswYEkf2RO+IzIe4G2FS8vWde/HrXf5qFxnrJcZ9oRFepBgjG804LyGE0TtvBAAdTWPHLtbti0MhlrFO98dpZU+Qz+L/XSFNA61mgTCBsUNkaBQJgEc2Mnt7pFofh0KqD/ZwhWpLVdFO5cBNgpIImgRNpz6FqlHerJSqPKWpWinKV3LSkpcEYrZ+5iehACpMp9ElSnjppjy1cDd26tOb/mTMYw5zT3JaZgD0lEw+NemX3whmLX94y5eFxkkmIpKMWNRNKHliSeHsEUrKSaNzfuNHvVTnkNAZIHfeaZ0okqeR6gmje2Izm0DcZmgcJCBi3ilRE8JPgghU0A0dxkIY8pJCD/ogBd2nNQ0daJMgGhWLTpRBGkVohjLKT81hEjTT0U4biXCcLgjKpNsxhEqjwNLsuDQk3VlObVA6BJjCZmYtzakQ/3aaHOzg9DbICc4VfFrUlYq0n1f6p3cIU5e2tAYvcFEMIaKap6kap6qBuepgkAPNrUalq4lpRFbFqi7EfOWrYO3LXbwimDCg1S5uKStb5RLWulI1rm1l6tRImsdJjYQjFhEIRjIyWBkVVh2H/Ug8FKsjxgYkH489SGSBNFmGOPYkkJ3HPzrCWScU5LKfrUhjK9vZl2KWJKFN7Wh/+tcpBdY7triFosb5CMzegha12K0seusI2/I2t7q9LUGKC4bhAje5V1huK4IrW1tq01pZuK0XgKmE604hu8w5BXatqd1bgDe83g0FeQkkXlmgN0PqbQV7pcvHWxKsuuuIgIXek/8Bc1x0N/bFr3/0SwH+Cse/XEhAgAc8mwJv4cD7TeGCodBgAXMTwk+QcIJpVOH8Oji+gyLAh0EcYhGPmMQlNvGJUQxiHRSAxS128YthHGMZz5jGNbbxjXGcYx3vmMc99vGPgRxkIQ+ZyC7u8DdSnGQlL3nJNjjuk6EcZSlPmcpVtvKVsZxlLWf5yNlg8pfBDGYnb5nMZTbzmdGcZjWvmctd1kWY4RxnE4+ZzXW2853xnGc949nNb5bzn/9M5z0PmtCFNvShB91nVQCa0XAWNKIhHWlJT5rSm1A0KRyQaU1vmtObxoEKQB1qUasAB5029alRbeocXJrVrXb1qz1EW1jvz5rWtbZ1h2R9a13vmte9HkSufR1sYQ971sAm9rGRnWymGlvZzXb2s0c636dCm9rVtra1mH1tbW+b29nIdrfBHW5xW4m64zb3udENhm+nm93tRva63R1veesa3vO2971ZXW9875vfstV3vwEecB/+W+AFN7h8y31whS8cmwRn+MMhziGHR5ziFRfKxC2ecY1rQ9ob9/jHObQHA4yc5CX/DMhRnnKVr5zlLXf5y2Eec5nPnOY1t/nNcZ5zne+c5z33+c+BHnShD53oRTf60ZGedKUvnelNd/rToR51qU+d6lW3+tWxnnWtb53rXV95EAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The defining structural characteristic of the immunoglobulin superfamily of molecules is a variable number of intramolecular loops linked by disulfide bonds. The molecules of this family which play a role in leukocyte-endothelial adhesion are ICAM-1, ICAM-2, and VCAM-1. ICAM-1 has five extracellular domains, ICAM-2 has two domains, and VCAM-1 can have either six or seven domains due to alternate splicing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21198=[""].join("\n");
var outline_f20_44_21198=null;
var title_f20_44_21199="Long axis pulmonary artery";
var content_f20_44_21199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 268px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEMAQMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XV2UDaxGDuGD0PrTTycmikoAmO14/l4K54OORkY+p5P4VGRhsHsaWKR4ZUkjO10YMp9CKZQBLGPMARQAcjLHoO3J7DmnFEMYcui8fdGSxOD/AFH/AI8KiDEAgEgHg4702ncVgpaSikMduO3G449KbRRQAoJxS7j602lFAEkLsjDDEY54OO1bWlRz3MrKnmSOzDgDqS69/wAay7K3aWTHQYyWIyBngfrX078A/hzHJ9n1a/tj8vKCTkFtyndjsMEDH+NMzlvoeGnQNS0q1D3Vu8KyxgnK9ioOaoxQ3c92qosjt5gMaj/eXpX3nrHg7TdSshDcWyuAMDK+2K5/SPhhounakLqG0TcCSpI6E4p36k8rufE2o6LqGkYW8tJYGlTgMuMgJk/zrKmmf72WHJ69Opr7o+KPgOz1/QJIvJHmqpYSKMMuATwfwxXxfr2mPpeoTwOpWaORuDzj5iMAdzQhp2dmc+WdZCSCGxg/Qj/ChpWYcn/PP+NLIuRksSfeoyMetI0WomeaeJGByDjnPSmU5VLEADJJwKQxXcsPmzn/AOsKXzWx1xnrjv8AWmsOTzn39aT+dArDmkLAAngdPbjH9BTlldQAGPAwMfX/AOvTCPXvzSde9A7EjysyYz/nFKkzquAxH+R/gKjHX9M9aP0pisSNM7Ltz8ox1NLFO6jYp4P69cfzqH8aUelAWJXuJJE2uxI9z9P8KWK5eNCoYjioO1C4oCyLL3kpYliCT6jJoqvg+350VabsKyG54xSUUVmUFFFFABRRRQAUUUUAL296SiigAp6Z3jrnNMq7pllPe3KRW6M7lgPlBOOQM/qKaE3ZHoXwX8Jv4j8RQZVms43U3AHHy19yaDpsen2EEMCIqIir+QA/pXh/7OegNpemmOQAyuQzkjkc19BQYEYxjg9B2qb3dxJaklIVBOe9GRzz0paCitfW6z2zIVyMHj8K+Zfjj8Opri4u9VsFUEPlkUcN8xyT+FfUZGc56GsTxHZxS2EsbLlZAQefX/8AXVJ9zOceqPzeuIhGTjAAGMdfWq5U5YYHHJwM8V7H8UvhtfaVJdX9nb/6GuWfA4A2uSR+Arx+Vds7JnBDFf1psIyuQ8dc8+9LkH/9VIOmO1KOTn+dSaAe1APocUlH40ALjj9OlAOB39aXqf0wP0po4PtQAo9vSjrkk5PrQB2wc0uPvYIwvNMBP6UdAfT6UD/OaM9iKQB1z+nNGMc847UdMEUmfTimBIrPj5eB9TRTNpPIBxRSuLlGUUUUDCiiigBaSlpKACiiigBaSiigBy9f0r6R/Z0s9DXw5JNdxxvfPMwLOASB+7IA9ulfNo610HhvxLeaE8f2VyED7mUd8lM/otBMtj7U8L6nYWWpvFAV24HAI9TXodjqVvPGCjDBxwD9P8RXwlpfxAu47xZC+NzLnn/aOa9Y8D/EnFq5mlxgKOW6ZWIZ/WpJTtufT0AjjL7XLb2LsWPIJ7f0p8zgKQD8x44NeLXHxQtIrcFJxt6E575fv+FFt8R7aa28w3AKAHgt6Af40XQOdj2aa6WME8EAZ6/X/CqGrXsIiUFlByDz9a8fvPiTbmNgJz8uVP8A5G/+JNchr3xVjNztRyV3FT/30KEwcj2HX0s9Yt5rBwhjZGU++VkHH618mfGvwdF4U8RL9iB+zT5kCnnaS7f0FevaL4q8y4E/nffPY9sy/wCFcH+0Bq9vqDW8QKtMvJP4/wD1z+NVGV7pkPdM8PPoAaPpxSH9KB6Yzmg3CjPI9qB3yRSdvagB/wBecfpSAZHv2xRu4xgYpO/pQAuPw9qMdeuKAeOOPejjacCgAxz60YJ/z1pCeaU8DBoAU45/pSf5JpDwaM856UwFJGeRzRSgqByufxoosBHRRRSAKKKKACiiigAooooAKKKKAF7UlOU4NGPlzkUAOjcq24VdstRmtWBjkYdOM8dv/iaz6UdOaBNXNibWrqRSDIfUc+7H+ppE1m5SIxLNJtIIAzjGRjFY9LnPX0p3Fyo221m4IYb3GSerc/8ALTr/AN9fpVWe8kkbcxOS3XknrniqROVPscAj8aaOTx94mgOXU3rHxBdwAhJCo5OCc9n/APiqra1qkuo3LSzuXbJUEdxkVmAsin5mXsf1pSCADnJ9vwo2FbUiPWgZ4pSORjr7U4JwM9/XoOn+NIojIxTmIIXC44wfc0N06elIvX6UDAYxzRmnev8AXmm+4oAD9T7UufcUYIx70uTyO2KAGjr60Anjnil6+9KBgHOAf1otcBD0AJyPrSd6dwDjnkelNPT370AA/wA80U9Vcj5elFAWZFRRRQAUUUUAFFFFABRRRQAUUUUAFPXoeabRQA4KWI6nNJ06V6f8KLHS7u5cXsaO2VwCP+mg9ai+IfglbOY3OlRYt9ikjHQeWP8AA/jTI57PU80o7VNJA6SMrAgg4OR3zj+lKImIbC5AHXHHCk0rFXGuOdoHrnA9zQE9G6DOas+QxkwwPL7Txz94g1oWOj3d6AIIGPyEj6bVP8jmqsS5WM2OJtyqoBP+BNX9M0m5vhi3hLr3AXPePv8A8CFdVpPgm/lu4ElUgNKoOeuC+M/Svb/h14St9O05TNEglMcZBP8AuQH+YpXsS5X2PnC68NXlnHDJPEf3mBwMetZ86Abc8DjJIxxiOvojx9ZWdssRRh8rBgOODzXz9qoHmkjGSByOn3Y8ULUSbvZmM4+bgccfypp9qlZjkZPBFR4z05xQaoOcHj9KQ5Ldckn86cBxjIx6+lHHJxnuRQMTn8uPpQPwNLkggHPSjkAZIx1H5UgG+lOz8vzcntTeh47U8dACOOv1pgxv05pScEnqTkdaMEDHtkUje3I9aAEJ55ooPU4FFAWG0UUUgClNJRQAUUUUAFFFFABSgEnA5NJRQBdu7OW1EfnIVDev+feqrjBH0B/Sr1zfy30EEM5JMZIVvrtH9KpmMlQynPHPtxTEn3NXw7q0um3sciEhd6scdsMD1/Cvo/wTrOlaxogS5CkmIjDYJ/1cv+Br5ZQ4IOenIzXQeHdcutO80QysAQTgnpiOQA/+PVLV9iZRPorxT8ONIvlmuLWBEYuxGzrjzHPUfWuE0DwtbWsV3az2wLsSqnGf+WMvPrXc+DPF9vqULQySs7vIxKk5/wCWh6etbl+ljDE1z8v3GYgdOI5AaObQztqefR/D/wD4mEzpb5EkzdvWZuP5V13hrwxDpcUfnom4xrz6/u0/Kmap8Q7C1v8AyhIoYyctnt5pH8wa4LWviocJ9mPVAMk8fcX/APVRe6HZXPcINPsftsUgWMMkisfbEmc/rXOeMvE1podgghlXeVUBFP8As2/HWvEX+KeoiYPG5XD9D6bwf6Vx2veIrzWShuJiVCqoB4Awkan/ANAoSfUOXsdJ4k8YSatPhm53AFhkkcn8fxri55i4AbnIH54T/CqvnMMDJGDng0m75c+35/dqlpsVy2HP/D15/wDr/wD1qiIwOfwpxBAyBz0Ix9aB3BPXP50FLQQcLnoe369KUt82OgHAxS5wuB1A6H8abjA+vHFACDG7ngZ/CnEDB2g9O/4f/XoQHzE4yaQDC9CABnP1AoGIwUNkcikzkZJBNOIwRkn+eOaMcgfMRj6UILhn5fbPb6UpyRjHqfX6004Bx3x/SpraZrZt8DYfayk+xGOKBEDYLEjgUUoJx90H6iii/kMjooopDCiiigAooooAKKKKACiiigBwOKcrkKRxio6KAJVYbxnHXk/jXa+HrLRLuyP2lgsgiY45/wCedwc/+Oqa4apYp5Ig3lsVyCDg+oI/kTTJaud3rWoweH9dZtJfcm6TO1uwlbHT2Ap+q/EG6vdMa1B+9GyZz0BSRT/6EK4GW4kkbLMSfXPuT/Wuk+GfheTxn430rRI2ZUuZf3zr1SIAl2/BQaT7iULFfVtG8QW1jb6vqOmahDp90Q8F1NCyxvu+YbWIwc8ketYJYn+LP1PtX2D491Gy8feC/iL4d0qGHy/C7wG0CHjEa/MB9Nky/TFeCfDn4Van40sLvVZL200jQrX5X1C8OELAdFGRnHc5AH1o0auCdtDzkdiozjnB+tIeFGTn2zXoPxL+F+qeCLeyv3u7PU9GvDtgv7Rsxluu09cdDjk9DXn7cDB+ufyplJpiY+bGe/pUiqOMjPHQ/QU0DuPzqwgCxgAbmbjHXsOlCExGiOMgZ/ry3SmEDbg559qsyNli+MDJ6EkDJaq5HpkfWhCBkIZuvU5A/GmmM9V5yematSDeDzjnP/odCJ8vyjPv3xxQFysV2uu4Hr26daaeU98f0FXZoSGXcOuAOfUn9aqkHAGBjH9BQIbgE47ZwcfX0oUDgHOewHbrStkM2M5Bz+tCtz3yaBsZjgngcf0pdowx29M05sEgAHn0PB4//XTc4zjIwTg0AD7tx25YevPNFLlzyMY/Gin8hXK9FFFSaBRVyxsLi9WZreMskSlnI6KApPP4KagkieMsGHI65HTnFArrYipaSpY2C4yP88UDIqKklKmQlBgZNM6UAJRS0lAC0UqjPFLgEdCPWgBlFOxRjigBte2fAXxb4b8BaB4k16/uo5PEjQ+TY2TI3zjrjcBgAttB9ADXipHYc0q9xzik1cTPqr4W/GvSvEOv3Wm+JdJ0LQrS/t5Elu4mMYkbgBXJ45DPznrWbaaVJ4y+BD+EfCl1bXOraNqTtPZpKF8+PzGZXXP3gQQfrXzbEMnaRxuxgj3FXNMnubGRZbS5mtbnkK8MhRgMA9VppNaku2x7x43sm8B/s+2PhLxBNE2vX9+LlbRHDtbIGUnPtgY+r/Wvnp0JwM9gf0FdAYrrULjzb2ea4uXcBpJHaRz86DBY/wC9/nvNb+Grme3WZI3JMa8Ef9M0P9f0prYlySdzno4TI6gAAE/1/nUkUXyZ2FsKSCP93OP8+ldzovgm8vZ0BTaokA6c/fwa7LS/hqBaYlJXbEcHHJ/dj/P4UC5zyIWTs7KFJYscc84BkB/lU0OlSFXaRMJsYkng9K930zwLax3zMUBG84JHbdN/SqHijwwq3Gy0Tcdrnpx90UkxNnjX9nPHctHtw/zL06fNIP6ClvdOlit1LAgEDn3wvpXtc3gqO3l84qWJZhgjPO+Y5/SptL8DC7k865G2IHKjBxyEPNCYXPELTRLy4hErRSCNXAyRx97FZdzYPDbhyCBjLZHqqn/2avoLxbFa2GyGAbVDKAMDj5+cgflXkWr24ltxwCuxTg/9ckP/AOqmndDUnc45wSx+Ysecn8aQgDtjPXjgda0b+1ZZiUG1RkeoHzcVTCthSeCMYxxjr1plLUiO055+bHOB04FNZcHB9OlTFTkBQcbd2f8AgIzTZUTaoRyx2/N8v3T3/CkFyBiCxzyc0VIzAsSQuT9KKodytRU9nazXt1Fb20bSTSsERR1JNekap8JtU0jTlublgzhFd1Ufdz2/CpSuOU1Hcw/AN5HbRX8LqCZUJ574jkP9ateKNBR7u5uLPndI52jt857fjXPWqzaddjehB8sgrjHWM/416BEJXP2iH5onkOAO4Lg8fpRszKT6o8paIrJsb6GrEunyx2guCp8s9z9EP/s4rsvF2hwywrfWo2ylsMnbq3H1rH0i7iuLGS1uWwioSrf8AXP/AKDRoXzM5g5B56injDdRzj19jWlq+mvb30qRhWAJ+7/vEVnbHTqCMjP86LFJpolS3Ml15aYIL44z3YD+oqBkZSQwII4NaOjz+XqUTOOBImV/7aKcD8q67wpolvq+qZkjEkUmwbfQYOc+9AuZo4FQeuOO+Pwphz6V76ngPSIr9DJF8uFOOvaH/E/rVfxJ8OtFni3WTGCUIThe/Eh/9lFDsL2h4WDgEYzn9Kmt43kcJGCWYEAfga6bVPCJs7q4jjuN4iDHpzwB2/GqOgsmm6shn2t5e4kdeiuKT0HzJrQt6f4J1e7lKrBswxB3H0IH9f0qZvAurLM8YiJAJG4cc4b/AOJr2Tw3r2nyTkqUycvuyOPmT/Gul0+6sbtn2lcs5Azx/wA9BS5rEJyZ80aj4fvNKkQ3ERU78HHbBT/EU/StMmuMGNWKAAke+0dq+lNQ8IWuq3kbyHKl1P1+eE1b0jwNp9lbLEiDOxffPy1TasJNvc8m8FeELq7vrd5Iz5ZlUkFeMCSH/GvaNN8MWsdhHmIKPJUYwOMRjitvSdOt7Ro41AGGGO38UX69KvzRHyUUAbBEM9uiDGPy/WpdxpdzLstDgikU+WgUOSMcn7+aq37xLFtQ43Ic546Rj+gre1G4FuCcYIbPA4xuryDxDrksssqglUCEgD1Ef+NLoJ9jtZNQgto5WZlyrsPrl5a5+C7bULt2VeQjj8NlcmdSe5vJEZmw0pXOck/vJv8AH9a7nT7ZLWy3RjIZCAc8/cNJDe51Gkaakk0n2kKyhjgnnnfIBxU2ulLPT38naAEyAOnRBVaC8keVYz0aXB9B88gIH6VU8TXRGm7QwLbRn/vlKcQZ5F4jkuLi6lYFTtIA9j5lcK9vJJbqigkeWAMjOcRjIFejPpFzc3QdifLaQZDDr+9FZUdrHaxMfKCkRgDPHPkqMj+tNaEdTib3TmYsgHG45OP9v1rJ1TSJ7SNWePMeBsPT+J/8K9XtdIF65b1LMCeB9/vW43hGK8tFgmUFGIAYfwEl+R+BNUmVe2x857ecnPC9uo+WonyeeAOvHSuq8XeGrrRb14pYm8snMbYwG+UEfoRXMHaUx3GSKbVilK+ozp0JAoppGe/60UaFfI+jP2c/h2kajxDqsTCUjNujr0B2kN+OTXu19YwT5injDoQCT1zz0qbQLeK2s4kiRVQLtUegG3n9KvvArAtgnkDk980kTvufOfxd8EJ5Bu7ePZsUs5XP/PMkfyArhfAd+kOorBc52IzPyOvzJ+VfTvjPSo73S7mCXBJRlOCRnKOB/ntXz3qXg5tP1OSSDqXYHt825ab1I2Z6Jq3hPTddsC1iyiVlBG08btx4r538Q+F73Q5pDLGdgXhlzz8ikn/x6vQfCnjqfTNZNlcuSPMCDJ/6ac/pXe3smn+KtGeJkjZ5Ixyvb91nI/KkpW0Y9Vqj54urjzleUMSS/f0Ln1qENAYBvO5yMDByQCsg+vXFbPi7w1caHq8sKxv5W87SB0G8jFc3cKUOOSMZxnp94YNNqw1Zj7my+dniHVzjbg45X/4quu8FSajpt3byhS8Y2HCjOBg9MVyImcSAkcK+NueCQUzXf+DvEttHbQJMgBysbk9CBnH1pSDVI9P0PUv7RtVaaNlkKjhhjHEJx/8Aq/rXJ+N3udPeWVGcxBcZP+7MOfrWnYeJrF1UooUhQRx/sw/rz/OsPxhrcVxFLGCrKwJUj/tvz/Kp62JseWatqk7X9yd7bXPI7HgVThjutSuZRaQTXEz5cpChc455wB056+9N1NxLdzuo2qTn9BXt37Hdtv8AiJqc+P8AU6awGe2Zo+PyBqm7Gi20PE7bUrq1f927LtGAOmBkH+grqvDni+6tpolkd9u7czZxn72fXHU1ymuSm41m+nPJknds9Ordq9O/Zr8KxeIfHiXl+if2Xo8ZvbkvwpK52A9iM8nPYGk0h2urnpHg3xlHcwLI8gHKjtyQ1vwMf7wrrLXxJBcWsTrKOVXABz/DXG/Gq8t9Q8N+GfHHh628ixvla3kVU2/MsyFScfxHy3GfRR6V5Jp3iW4hs0jEnzkDABxxtpON9URtoz6Zj1qJVViw3bx0x/eh/wAauRaskkAKldwiwMn/AKZ14JpHioeXCsjsGDg9eT89v/8AXrpdE1yWWCF+cmPON3/TNuv5VLC56pezCeNsttDN3HIG+vPLvw19oRzhfLMbfKB3MZ/wroNP1QvdlC2CHJAznI3+lb7NBbaXLdyY2xwvM3Tosbk/yxTXYXmcfZeDzBqE424BkZuQSf8AWScf5/8ArV1v9nLb22cDb5ZHPOPkPaue+EOqvqnw90q6uZnkuB5izOxyxYSy4yT7V0c88l5Fs54jbgHORsPeknpcbjZ2IiNl1tQYw+enbfIKinMbpF5qhiyAHtxsSr0Nt++O8YJbpjkgSN19qyNemEFm0isu4Jj/AMdShA9BksUTusSDBZhhvU7x0rjNR05WVdo3OUAIAzg+UBx+X61sxzzSuJA2DuUkLxx5i9a1vDWlrNGrzrxsBPcj91jP+fSnfQW70KOnaY0shJTYuWHXH8Xp/hXb6FoQnUI8Y2BwCDyT8x7VYh0cCY4XcBnkY4+brxXX6XbJDEARlhzkdPvGgpI878feCbXW9Ca2mQeYi7on6EHYP8K+QfEmlT6RqV1Z3I2tEzAE9D+FfePiBc2QGcfLye4+Wvlr406V9s1B7yCM5j3LJtGST1zVp9CWrO54tJ99sgZz2oqzcAec+WdTnBA6A0Voti7N62Pu3w7qSyjYxXLcg54AwtdMGLxlo8cngdxhuf0ryqyn8qOLY+ZCuZcH/ZTiuwtNa/epFu3M/Qg8Y3fpWW24k7l6+tHuEDjlcAAdsYbmuH8YeHmPmSWoO8Z7AjPyc5rvRdAsoUgx7Dg+2GyaSSJbqQvjhgRnnodpzTuJo+Q9e8Mzxa1iRdjmRSWx339c1d8B6pLp0r/apMgRgknPA8lsZ96+hfFPhK31NwyIA5IUkHGAGFeOeI/DU2lQkLGSyx/OVHQeU2OfxzTauiE7aHoFvY6drYaR4UJVmOWGf4v/AK9cV4v+GltLMzWaKqspc4HAbElT+FdWmWd4skhHJIPf5hnBrvLXVUmbZLtPOBkZJ5kqLtLUdkfPeofDrUIS7RRsy5yOME8xdPzNcnNpF/aTIgicfMOR685z6V9lG0tprWIAfNhc+hx5XrXIajolhFqyh448HYRx7npVtpgro+e9I07UWg3IjhQD1+kZrZk0K7uZ2QKzglsA/Wb/AB/nXuU2l6bDYNHHGiZjx8pGCNidPypNGsra6M0jRDJYjGOclpfy61N1cNTwDVPBdxBZPKkQ+UEHK/7Oa9C/ZgvtO0DXvE41nUrHTZHtlhia6lWMOfMYHBPXoK9Sm0CCexZCqlQjAE8fwf55ry/xv8Olu7t5YVwAW7f7c3t7j9Kb166gpcu+xha58FrW103UNSs/HXh+6FvG83lrJ8z452j1J6V23gK98N/Dj4GxXPiKKW+fxRIUntrRx5piKsAp5GAF3Z+teP6n4HngtmmjRdioW6YIwEP/ALNXNWunObuGMKVMjgMcdOSKGnuWpRZ9MQS+F/G3wR8S6P4HtLy2j0p0vkgvG+aNs7yV5PBVZOPWvme0wsq+Y2SADnrnIPFalhPeWysttNPDvUB/JcqGB8kYOCM8EjB9T60sGjzsULHAOOnbg0K60YuZFGKRyVCnOxlOB/vRf4Cuw8K3s8MJdgxUJ8xXoCY5P/r/AJVmw6SIr1Nysy5Tkcf88eg/Guo0+3jm049FZkI444CSjpz6USJud3o80Al8wsAzNkkd/nFS/ErVm0/4Z6pLEwJlhWBc8Z8zdGR/3yzH8KwdLhZEbL7mV8YUk5+cdaw/jZqnk+DdL0ssRLNcCXHHKIHHP4uv5VEdxrexufs3u0/hO+jdwUivQoBPADID/MmvXIYEjjYAABUIA9PkavC/2ZLpgdftWOVP2eUDI7MwP9K96vNsFu8v/TNhyP8AYNSaS3F1FkAPl4B34Hcg729PrXIyK9xuD5A2gnPpsSte6kkuZiIyQBKPl6AfvOnvWdLZzDGwnDKM57HYn501sZvcWKyWNk7guA3f+NcCui09Bb2oLggKgyQP9g4qjZ2flHzJgQVYE9x99f1qGS+PksjH5ggBOOv7s8elD1RS3PRNNuLSNGaZHZwTjYwxj3/GrE9/FHIDBhBkBQx7ZOf615zca8LLBeTH3gMd8kVz/iDxstm8P7w8ur9e289KVx3O817WozBIGbH7vge+3NeGfEDVIpYpRGFyNykAcfd/SobvxZLdmUGRgHVccesf884/SucumaZZWmZdysxZQeSNtUiW9jgr3TGN3KRhcsTtLdM0V0l/bIl3II2ZkzwQB0x780V0KOhHO11PXLjVFt2iJmxvy7/7uE/rWro+vC9AniK5kJwMfdAavn2+8QT3Vu4SUhjGNxJ6DCdK6bwTqUyWrRswU5J+bOR84zWDT0K6H0LpWvLLKId/zDAQk9E+fmu2tbhGhQBuMbDg+y814b4SlaeZHc8nbjv8uZK9N0+VlhWMEfP8gOedu1eaSGmdEGLMSR8rHavPYOKxb/TUvI5S6AiRdjDH+w4FaQ/ebQzE7ztJBxyGB/Cog7RQ565BznqDtcD/ABqh77nCv4RS1v5poV5DsMeuWFO/sryNRiIQhFKtgduXrtZpt5GVzjO78xVV4dzbypY5xg88AtQ2TYxnmaFdw3MAiqAPpFmsPVY57uVGVRuBHQe56DvXVvbbrJiCRu5GRz0ixVcW586J9hADDjHuaA3Ry1np8kkUhmDbRGMjkc+UvX8q6qK1jtN7RNgMx5/4FJVpYUZXjC4/d9x/0zH9ahuICYiv8Qc4J5/ikpMLFqOQ/ZW+UEMpzk9PlrO1SZi8itHy0hByOo3yf4mprJhHCxduApJGBj7hq/OYXu/KbDFpfXr87ZFD3H0OEksWu7Fo5FwWQY+X/ZjxXlt3oE8GqqI4GIEynJ/66H/GvoZYIzKq4BUqvIPbYnpVKXR7Z7ncEDN5gJPYfP1p3Ja6nz5Dosk8oJhw2xMYXjgW5/8Aiq2TpDm2jQRkKwA6ema9ffQIEihkEWSVAI9tsNWU0KDbGjonLc4BHdqGwtZHjSaNLM6CNMMduO2f9T/hWzp+gzNCsJTClTkY9pQK9Jj0SOK6idV+UgqcjHOI8fy4rajsYUkd9p7/AJYkxSkxpM4628MpAxkKEbT8xHU/MOaw/HvguwvdP1HVdS/ef2dpF0La3YZUSGORvNz6jauB0zz2r1htuRtxyW6dOo5rjviYTB4O15FbKfYp9rY/6ZTcfShPUTVtTlvhz4StNPsvDPiCxZbdrjSUhvY0HE7NtZXPuOc+vFd458+0kGMr5Z4HOTsasvwKjv4E8Nbm2j+zrbbzkD5Qf6101oEjjZXCq20jHHOFbpU30uX1Zj20Je9Jb5QJOg7kSCr8McflgbeQoYZ/3Fq7JEqSnGOGyDgDJ8xf/rVleaBH+7OcKCCe5Ma0dBEss6YwePn6j/eT9K4/WdUhtoQVyX2Y+v7ts/59xWhrcksd2gjZyrEEgdD86c155r05Nqdu5iI+p/65vx+tOwip4m1iUXbLGwKKW2jOQfmFYEzTahcxmSQmIMpGD1/eHI/U1RnumknPmDJTJAPQjIp95dRq4VMKA24Dpg+ZTtYXQlu7i3hiQqw2lUVh77P/ANWKzJZpp55MOx5IwMcjbWcsiXMa+aQVwCSDx91v8Kbc33lbSoUNjaVHGflp2GF0+64c9OelFc/dyNJcyOXlXcc4HP8AWirSJ9lfUhspR5jB2Owg5A/D/CuutLsMFNuV86QkNxghQ4/SuFVsZ75GKsWt3LBKHVuak2lG+p7T4c14280QLBQF2oVGOMyH6V6DpPih5tr/AMG3aGIHUKtfONjqUk09rvLZ+VAw47v/AI/pXrfhifydILAn5o/LXgcMESpaId0z2vSdQS9BkjYjBGOeeGGTWoZVaLawIVxu49lfj9Otef8AhbV0iuGAdN3RcH/aXNdpBdRXSK2PlblfXAEgP9fyouBopACjFhw2SCw6HipdhCRqwwWIHHrk02VwUcDknLj2xioftCfaOfuYBwx4J3HP4Uw6Fe4OIgE6pgbR/ux/pipYkzPjGd2MYxgfMfahXjkwwIIdQpweh2xnNOUhBnPKv6erGkHqRso+zF8MCFIORj+HtT7qy/0lkBwCSc56fPJTDIqpJGCWBXIP/bPrUkt4plBYru3kH/vtqb3Ha6Mie2xBIDu+VM5x/sGmi3aOWJy2S8oA4yP9Yc/596t3VyrCUK4xtbqevyGojKo8olz8k479P3mefyo6i6E1soUoP+WhhABPIzsTH1qaFgUD5BbzAC2MZO8dvrVKK4VZIyx3KVXnPT5Eqa3l3RskZziXgk/9NB+lJ7j6F7cv2WFVQdBjJ7bIqWVgsqgYwBy2Md2qmXwloGz9xTx0HyR/4U7cUnkZx14Ge+WbikBXZBIWd2bpgEN3wnP/ANerTTHa6yMVmCtgBevEnI9qjwxiXA6rkY7DC06ZfMdmyFAJCODyOJaAXmSRuX3nB4yOnBOa5X4m718I65wMf2fcZHcfup66iO42SNBMpEvLFem7GORXIfEy+jXwd4gJIO60mUZ6nMcw5/z2px3RMtmP+Hski+CfDiqDIpsbcAt/Cdq10VxMPsxErghU9O+1qxPADL/wh+gBVVV+xQBj05CpzWjOEjPPJ27iT/utUL4SnuSXsssbRggyxB1Lc/MPnXv361lxagjQnYVIRVLfTYMfjRf3a+YB/AJMnPXHmR//AKq4q+1Dctuyvh8AO4OOPLB5pvYm+p02pXG2QluQrBu5zl04x0rz/XLsQRNGu1m2EAnqQY5CfrVufV5t6RTuAFf74XAOWjwMVzurOAhlkOWjABz3ykgp9Atc5jUiGnmkiC/6xug+lZt7MPOXaGBL+2f9Zz9eprT1WdVExVdrEnBzj07Vz1zI0buC4kffuygyB84NXuIgjmPlDJAXC9DjPytVaY4Zjj5sk4B56d/WgSDj5sKQuDjOOG/+tSSFDjnJGFOeB05FN6l2KVy2Jjgg8Dk8E8UUjnLHgn3AopWLTK3alQ4YHFNqRDllB6ZpFFu1lHmxc428dOhycGu903Vj9mijRuI41Iwed2xMmvPlhkh3SHhUYDP+1zj+Rq/YyFCzpIcKm89s8LkU7Gcke0+Hrlo532ucq+QM4zl1yK9A069li27TlIxtJ9QVk7+3vXgWka1Lp+owiZiY1JLN04ZlIP8A9evTtD8TRCwgV5RueMgjPOSJgPr/APWqWrEHq9le70LMcqp29cZXg5qrLdMqSFn24m6jAyu41hQaoq2i/MNzQlGIOPm+XmquqazF5kFvGw811WM8ZAbcetAXOg0q6PlsrEAKisvbAKx9P510LGN5GwwIfux7g+lcXo92rw2bOu5WTDAnk4ji71o3WolPJO85Rmzk9i5o6j6D9V1BrWOJiRt8pwTjn/VmsKbxKgurlfMG4SHA5yfnk7dawtQ1wm3vY5CSIk4IPrET1+lcrqWrCPUJGjQlJQ/T/rpJg0CvodfH4hkku2Ys4DLkZGP+WZrZg1oS3ZiVj8rkkn/rqAa8kXVWewj2t+82bM5x/wAs2q5puo3Ntqx2y5Qvzk8/68f0xRbUG9D2OBmWKMuwXciZPcny0PWotIvh+98xskSAYGP+ei1ymnardX1tYLwM7QSf+ucdR6dcy20c0YOQ9wQD6/vV7UA2d2l+/moXlHk7E8tMc58qPcc/X9BVs3ZdSytk7hwT0wzVwUN1M04fczbYUPPU5ij/AErfsbpg0CkD756n/abil1GdXDMHLkv8iKBgcEfIO9E0xeIqH+Yk4HTnMvb8Kw0uD9inlEgwcAHpkbF4okvkhuHRmYhdw5HX/XnNIaNDVXOXZX+YZCufqBXH+KrBta0q909p/IaSJ4mYDdtbbNxjjI4/ya2NSv8AMZdwdzKXyDycY4rnY9UeXX7OUFtsl3GrA/3S0wJ+oNDdlcS1N/QoZNI0yzspBIBbxJFuddu4KVGR6Z9M1De37zeUIxuH3SyjPG1q9G8Yan4st9Xmj0LTjdWSouMxqQzHaTkkj1NY/iiGH/hNfDLRJHBfyuv22KE7ljbA257Z5b8KJLlWg9WcHePdJeBniljDOsbEqcYEsfXiuYvUxBGwGQ6KOpBH7sYNe5+Itf8AFFn4ulttPsftGnqY1UGA4IJj3Ev6AM5/4D7Vy2v6DZ6j8YLXTbVEFsWW7ulTgR7UBIHpn5fzqnomSo6nkGsm+j8ttViuoElwU8+JkJAePDLkDP1rmJbyS8gHmZ3RqA6E5ySsuDX0H8SpYfHfgu/1C1RA+i6m0IKHJaEFQSfbPP8AwGvnqSKOFd+WAZeSf4TiXH1H+FPS2gJWOe1d2ieVW5+9lvXpxWM7nzc5wc9AeR81aOtzs9w3mR54xuA4PTn2rMZv3jMD0c4I7/OOaocVpcXb8qsDkYAyTz0NVmfK5J3HpknOOKSSUspGeuMexwaR/l25ORt9fakUMbk8Y6Dqf/rUUHnklRx60UAVqWkopGhaF0xiMZAIJDH3I3f/ABVM83knkZGDg9sCoaV2LsWY5LHJouKxfF28znzXLb8BiewBGMV0OgamjSRxzOV2ruU55G1JD/UVx6nDA+lT28rQ/OhIIBHHuGH9aBOJ7LqGrS/Y0S0mXeW88YOcgbRxWQ2um38gTsTKJxLhSD8u9uDXD2mqtHMWeQ8RmHpyRkf4etWrO9S61W38wZ/eJF7lfMP680WMrM9Y8P8AiMG3be5AWGN0Xp1iiyc/WtrX9XQR3aq4LEpt5x/GeleZ6bBJJaWZizsmBRznsscWP8+9Q299PPdQxXW8LuKsDx/GcZ/+tR1DoXX1C5lkluFY4uYSVHY4gYVehl+0+Wsi8rujHGBgyyZ+tR6ZpH/EnhZiWZY8DIx1jfNdlb6QBcXGwDct7tPHJHmt6UtEw6HmRsb1pZkiDhIg3J6Y8s8V1tloV3DqSsQdzIspyMkZnGc/nXax6QkbSEKF+Vmzj/Yb8a6SG0hbUh8vW3QHjsJV/wARTvrYXQ5Pw9A8VrYKN2/K5yPvfuk6flT7azc7WIILXTZwM4xKp/Kuot4oIIrLcyBRgEEYAHlpXNXWpQ2yQHJ2/bGHAAz+9Sp6jew+W7WKzuJSuSsMZ+v7uMU+XUwbtFjToSM5/wBpuM1i3t9A+kXrF1H7lCQcj/lnH3/Hg1QvbsLrEvluvkqQOBxyzUbsOh12lXbSWSL83zjPPIHyit6R0ZbqTAyr4BPUDM//ANeuG0vUooPIQMBiF+vB4jFTalroihhHPzbmYYxyGuD9T0/SkwRua08UPnuh4TK49Rx+X1rmtPubYaxZMSqxJIGZmOAmGnPP0Gawta1qS7S58tgAXJGD1XAOfpXIazq7SecIG+WRyPwPn8j88U2rqwLQ+jvGfi2RPG1ydM1R2iWONo2t5dydI8gY4PJP6103iHWdKn1bw1qSz2oMjCWZwwGMDqx9vm618hWOrzWtw64zljEC2eBuT09hV/8A4SiSSELvCgx+UCFwchW6/wCNJxZSZ738T/iNf2Hiy4tdH1pvse+Pb9nKsuD5IIzj1LfnWJ8LPFOn6FoHiTxHqF7BcaqyrHDYzSgST/KGYrnn5icH/drxwXf2ma1kLEq0oQjP3Rvizx+P44qKKdYjbM+Rk4ftxs4/zmqa6iUu59EeBPiFoOrz6ho2o6LYaFY6hbyebMk/ySMABhiQB0Y189eJpGtby8skmWUQyNH5kbApJt80bgfQ9eKr3tz91jtYKSCrZOOU/Ks5pPLVo88pgFu+MSkinqL0K87mQPMTgHPPXBIHFUpyvmY4BD/+zdKfcu0jSYyA5LgD8PSqcpG5sdOQR6fN9MVRSViLjHoDTccZBHPH6U44GB06deKYBxuwQD09RxQVuMckEZyOAevtRUhkkU4UHH40UXHdFaiiipKCiiigBaemQp4/H04NR08MQpXsSCf1/wAaAAZPTgDmpre4MUqyA/MrBhx0wc1CxH8I496FO+Rd54yAT7UCO40vxOlvZGGRVby4wVJ65KRj8+DXWaitvKl3Ig5iMZHyg8tJ2ryNcFBtbG4FSPoFrvfDmpfapIIpSM3Lbm/4A+RQZNHXabZTyWs4cFFKKVDeghevQNMsyLm6ZyPnleTPUn941cdZX0Mtnb7SRLLaSyZHqsMlbOm6u32hSCMSwSNu6f8ALVh+NLqS9joC7EOFQ82hbnudjd6mtrh4rwbeMxAZPc+alYsOqhLYLtG5tOKknt8rVDBra/2hGHUAZVSc5GRLGOn4/wA6XUCS/wBTdbG1DAsd+M+4jTpXkt7qs11dwIHbaLts4PX96vArq9S1o/Y7RmJJeUjaOoXy0Oa82sr4R6zDJKjFftJYgHHHmqc1VgWxbm1K4OmHnh4hnHtHFj9BQdZnFxKwYLl1JPr87VFd3cU+kWClAJNkgJ6bv3cfXH0rOuGDSuyrgGQHaR/tt3puxR09zdyQvdzSS4igAj/76jA4NP8A7VWZI4ZCd8YkXOcg/NcH+v6Vz+qXglj1F+V3mMovqdgB+v5VQkuJI5rhlfD+Zge3Muf50PcSWh2bXdtEIkaRdzWchO7pux+tci0wcv8AMNpRse3+t4/U1FNcFmnYsdysUGD0yP8AGqzZLyAYwGKZH/A+PyoGkWC4WRDIRhyCCOo+ZTn+tPiYMNiHeVTfn1GG/nVLnzQpwSW2cDrytW7dlURb2C4YJuJHTDcf4U2x2sdRptspLw5UOFSVMY+8Xg5+uCKkupY3jNuHQLLCkaFR0OzJrMtbzYIW4DJIAWJ6gNFzWT9oc87gCgBAB9VIFS0SrmvcyRvt+bCnKkfTZisea4DJEzDJ2ld4PQHeOn0pvnOgeMn5uikHJByhI/SqgdDuwoKnBGfbdVDSHTY52kHBJz3xgVWeUl2we5IOOeSKGyq8PjggfN2x0pjOzEDj5T9O4GKNyhmcDjHHb160g54z0H5cUdht6evr1oGMgA+/I68UDGMxBwAMYHYUU4gnHzqOBxRQPQhoooqSgooooAKKKKAClFJRQA/cdo5PBJrS0m6MF5bux+WInjPIyayqlR2XcynDAg8UCavoddomo3IWIBmYx28sQGf70MmP5V6jpscgaFifmjWSDGf+mrflXiFhcywRTeWxB4Oe/Mbj+pr1fS9RuGkZCwx/aBTgdvMJpPcykbCF1twwbb+48rkYA/dsaqQShtQglkcAi8EBP0ni/wA496p3l9OtvNtfgTlcewjauYXUbnPL5I1Z8EjkYljP9KES9Ua9xIn9lWQXktMwJ7f6tP8APSuHtBE1/Zglebt88cD51xzUst3MdLs1LnCXTY5/2FrFSV1li2sRtmJGPqtXYtRL0Eqx2do7ZZSZABnvsUVXjnRZogVyMkn3+Y8VTVyY404wpYj8VH+FMdykwIAO0nGRnuaV9SuU1L2czRIpO75Tnn/ZH+FVJQ5Zwe5LAAdgX/8Ar09Di3gbuYpM/lj+tLMuYI5MkN8y8HHeSi6FsVWb5M5zk5555qYzj5/7zPv9f73+NVh8/B6BSf0pZCQkff5e/wBTRYdi4GLSu+4Bs78Y91NWbbfOGVeSsW4Ed+vHFZQJKfkPp0q3pcjRzLt/iCqfpmi9hNGxbqFQg9WCqpI4B3QEnH41SlJKxDPyMoU9OympYJnkktg5z+9Az36xCq7/APHs/bZ93HbINHkTYqSKVyzbs453c9hTSSFKtkEHt1/iq3fNkSnAG5VJwPZaoSdQe+Cf/QqCk9BJHL7jnrz9eKaScnPXp+oqIscY7VKOM4/zyKOpVrA2FGB2P59aO3PTIzxTUJyKVRynvTFYY/X8B/KikPPX0oosUf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right pulmonary artery (RPA) can be seen in the precordial long axis view as it crosses under the transverse aorta (Ao), superior to the left atrium (LA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_44_21199=[""].join("\n");
var outline_f20_44_21199=null;
